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ABSTRACT
Purification of Sterol Carrier Protein (SCP) from rat liver is 
described. Lipid binding studies indicated that the purified SCP 
is a fatty acid binding protein. However, no cholesterol binding 
by SCP was observed. Antibodies were produced in both mice and
rabbits to PAG-incorporated SCP and to native SCP and the
specificity and sensitivity of two of the antisera was determined 
to be adequate for development of an ELISA for SCP. Further
treatment of the selected antisera is discussed with a view to
development of a sandwich ELISA for SCP.
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LITERATURE REVIEW
1. INTRODUCTION
)Numerous small hydrophobic molecules are involved in the 
metabolism of the living cell.. These molecules must often 
transfer from one cellular compartment to another as they fulfil 
their biological function. Within the aqueous environment of 
the cell, the diffusion of hydrophobic molecules would be a slow 
process. It is not surprising, therefore, that much interest has 
been generated recently in a family of intracellular low 
molecular weight soluble proteins which have been implicated in 
the transport of small hydrophobic molecules within the cell.
The earliest report of such a protein was by Dempsey et al., 
(1964) who noted that an unknown cytosolic protein was required 
for the later stages of cholesterol biosynthesis. This protein 
was subsequently called squalene and sterol carrier protein 
(SCP) by Ritter and Dempsey (1971). Numerous similar proteins 
have since been described and are listed, along with their 
reported amino acid oomposition, in Table 1.1. However, as will 
be shown later, it now appears that some of the proteins which 
have been isolated by different groups and given different names 
are identical proteins. This results in a certain confusion in 
the literature relating to this area.
To date most information is available on the protein known as 
SCP. This protein is unique among this group of proteins in 
that it has .also been found in serum and is, therefore, not 
exclusively intracellular. Its association with the lipoprotein 
complexes in serum prompted this study which aims to clarify the 
lipid binding properties of SCP and begin the development of a 
more sensitive assay system, for SCP, which would aid 
investigation of its role in the lipoprotein system of serum.
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TABLE 1 . 1 AMINO ACID COMPOSITION OF SELECTED LOW MOLECULAR 
WEIGHT HYDROPHOBIC BINDING PROTEINS
A.A. scpa DEAE PEAK I3 SCP2b FABPC Z-PR0TEINd nsLTP6 PROTEIN Af CRBP8
Asp 11 14 13 11 11 11 12 17
Thr 12 9 4 12 12 6 10 7
Ser 5 6- 7 6 6 11 6 7
Glu 17 14 14 17 17 15 19 19-20*
Pro 2 4 4 2 2 5 2 4
Gly 13 10 14 12 12 18 12 12
Ala 2 10 11 2 2 10 2 6
1/2 Cys 1 1 1 1 1 1 2 3
Val 12 9 6 12 12 6 10 8
Met 7 3 4 6 7 4 6 4
lieu 9 5 6 9 9 5 7 4
Leu 7 11 12 6 6 10 6 10
Tyr 3 4 ■ 0 3 3 1 2 3
Phe 6 5 7 6 6 5 6 5
Lys 17 19 17 17 17 14 18 12-13*
His 2 2 1 2 2 2 2 3
Arg 2 4 0 2 2 2 2 6
Trp 0 1 1 0 • 0 1 0 2-3*
a Dempsey, et al., 1981
b Noland, et al., 1980
c Gordon, et al. , 1983
d Takahashi, et a l . , -1982a
e Poorthuis, e_t £l_. , 1981
f Ketterer, et a l ., 1976
g Ong and Chytil, 1978
* CRABPis identical to CRBP with these exceptions
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1.1. Intracellular Low Molecular Weight Hydrophobic
Binding Proteins.
1.1.1 Cellular Retinoid Binding Proteins.
Included in this family of proteins are Cellular Retinol Binding 
Protein (CRBP) and Cellular Retinoic Acid Binding Protein 
(CRABP). Both can be isolated from rat liver by a laborious 
purification process. They have estimated molecular weights of 
14,600 and 15,460 Daltons, respectively, as determined by gel 
electrophoresis in SDS for the former and by amino acid
sequencing for the latter, (Ong and Chytil, 1978 and Sundelin et 
al., 1985). CRBP has been reported as having 134 amino acids 
while CRABP has 136, details of which can be found in Table 1.1 
(Sundelin et al., 1985, 1985a). Partial sequence data have
indicated a high degree of homology between both proteins 
(Sundelin et al., 1985a). Both are ubiquitous and can be
recovered from all organs supposedly dependent on Vitamin A for 
proper functioning (Bashor et al., 1973; Ong and Chytil, 1978
and Sundelin et al., 1985, 1985a). CRBP and CRABP function
specifically in the binding of retinol and retinoic acid, 
respectively. However, Sundelin et al., (1985) suggested that 
the pattern of tissue distribution indicated a function in the 
intracellular transport, rather than directly participating in 
the molecular function, of Vitamin A.
1.1.2 Protein A
Protein A has been isolated from rat liver, as a by-product of 
the preparation of aminoazodye-binding proteins (Ketterer, et 
al., 1976). It exists in three different forms each being a 
single polypeptide of approximately 127 amino acids with an 
estimated molecular weight of 14,000 Daltons (Ketterer, et al., 
1976). These proteins vary only with respect to their 
isoelectric points of 5.0, 5.9 and 7.6. The three forms have
been found to have identical tryptic peptide maps and 
ultra-violet absorption spectra. Differences between the three 
forms may be related to differences in fatty acyl-CoA 
derivatives found in association with them, e.g. palmitoyl-CoA
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(Ketterer, et al., 1976). Protein A has been detected,
immunologically, in rat intestinal mucosa, myocardium, skeletal 
muscle and adipose tissue. A role in lipid metabolism, as a 
result of its ligands, e.g. oleate,. palmitate, has been 
postulated. A known carcinogen, a sulphate ester of 
N-hydroxy-N-methyl-4-aminoazobenzene, is bound by this protein 
(Ketterer, et al., 1976). It has been suggested that the
mechanism of binding of this carcinogen by Protein A could 
result in the protein promoting its carcinogenic activity or 
inhibiting it. If Protein A, in vivo, bound the carcinogen 
non-covalently then it could act as a transport agent for the 
active carcinogen; conversely if it binds the carcinogen 
covalently it could inactivate the carcinogen and therefore 
protect against carcinogenesis (Ketterer, et al., 1976).
1.1.3 Non-specific Lipid-Transfer Protein (ns L-TP).
ns L-TP was originally isolated, by Bloj and Zilversmit (1977), 
from rat liver. They had problems of inactivation during 
isolation which can now be avoided by the use of
2-mercaptoethanol (5mM) and glycerol (10% V/V) in working 
buffers (van Amerongen, et al., 1985). This protein has an 
estimated molecular weight of 12,400-14,800 Daltons as 
determined by single band migration on polyacrylamide gels in 
SDS (Bloj and Zilversmit, 1977 and Poorthuis, et al., 1981). 
Structural studies indicate that it is single polypeptide of 
approximately 120 amino acids (TABLE 1.1) with a pi of 8 .6 . It 
has also been isolated from numerous other rat tissues and 
hepatoma cell lines. The concentration of ns L-TP is lowest in 
testes compared to all other rat tissues tested (van Amerongen, 
et al., 1985). A ns L-TP concentration almost double that 
found in rat testes has been observed in rat ovaries (van Noort, 
et al., 1986). ns L-TP has been found to be specifically 
localised in the Leydig cells of the testis and its 
concentration in these cells is dependent on the plasma levels 
of lutenizing hormone (van Noort et al., 1986). This suggested 
that ns L-TP may play a role in the regulation of 
steroidogenesis possibly by regulation of the availability of 
cholesterol for the P450 side-chain cleavage system. A similar
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role for this protein in adrenal steroidogenesis has been 
suggested by van Amerongen et al,, (1985) who reported that ns 
L-TP stimulated the microsomal esterification of cholesterol and 
its conversion to pregnenolone by adrenal mitochondria. However, 
to date, no evidence that this protein specifically binds 
cholesterol has been presented.
1.1.4 Z-Protein
Z-protein has been isolated from rat liver and its purity 
verified by single band migration on polyacrylamide gels in the 
presence of SDS (Trulzsch and Arias, 1981). It is a single 
polypeptide with a molecular weight of 12,500-14,000 Daltons (as 
determined by polyacrylamide gel electrophoresis in SDS). Three 
different forms have been isolated (like Protein A) 
distinguishable by their different isoelectric points (5.2, 6.0 
and 7.3; Trulzsch and Arias, 1981 and Takahashi, et al., 1983). 
Amino acid sequencing revealed that all forms were almost 
identical (Table 1.1) having 127 amino acids and one mole of 
associated fatty acids per mole of protein as isolated. It is 
believed that endogenously associated fatty acids confer on the 
protein its different isoelectric points (Takahashi, et al.,
1983).
Rat liver and growing hepatomas (Grinstead, et al. , 1983) are 
among the only reported sources of Z-protein. Numerous studies 
have demonstrated its fatty acid binding capabilities. Thus it 
would seem reasonable to postulate a role, for Z-protein, in 
fatty acid metabolism. Studies by Mishkin, et al., (1975),
indicated that infusion of perfused liver with flavaspidic acid 
(340 jjmol/kg) or bromsulphalien (360 ymol/kg) both of which bind 
to Z-protein, led to increased uptake of [^ H] oleate but that 
oleate esterification was decreased. They, therefore, concluded 
that binding of fatty acids by Z-protein was not obligatory for 
the uptake of fatty acids by the liver but that it might be 
involved in fatty acid esterification. Others have reported 
that Z-protein reverses substrate inhibition of acyl-CoA 
cholesterol acyl transferase at high concentrations of acyl Co-A 
substrate. Following this Grinstead, et al., (1983) suggested
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that by binding acyl Co-As and other enzyme effectors e.g. free 
haeme, Z-protein might function to modulate the effects of 
fluctuations in the concentrations of major cellular 
metabolites.
1.1.5. Fatty Acid Binding Protein
This protein, known as FABP, was initially identified by its 
association with radioactively labelled fatty acids in selected 
protein fractions following gel filtration of rat liver (Ockner, 
et al., 1972 and Mishkin et al., 1972). Co-migration with
coloured organic anions has also been used in its purification 
(Ockner £t al., 1982). Homogeneity of purified FABP is
confirmed by single band migration on polyacrylamide gels in SDS 
(Glatz et al., 1985). FABP is a heat stable protein as
evidenced by its purification methods (Billheimer et al., 1984). 
However,.most of its activity can be lost by improper storage 
(Billheimer and Gaylor, 1980). Trulzsch and Arias (1981) noted 
that the presence of glycerol (20% V/V) in buffers and the use 
of thiol protecting agents could prevent the loss of functional 
activity and precipitation from solution during and after 
purification. Fournier and Rahim (1983) and Fournier et al.,
(1983) reported that at concentrations in excess of 50 M, 
purified pig heart FABP self-aggregated into at least four 
different molecular forms.
FABP is a single polypeptide of approximately 14,000 Daltons, as 
determined by gel electrophoresis. Multiple forms have been
isolated all having similar amino acid composition (Table 1.1), 
ultra-violet spectra and being immunochemically identical (as 
determined by immunodiffusion techniques), (Ketterer et al., 
1976; Billheimer £t al., 1980 and Trulzsch and Arias, 1981). 
However, they, like -Protein A and Z-protein, have different
isoelectric points (pi 4.3 - 7.0). Studies have revealed that
various forms have different affinities for long chain fatty 
acids and it is believed that their endogenous ligands
ultimately affect their isoelectric points.
FABPs have been isolated from numerous rat tissues, bovine liver
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and intestine, rabbit liver, human adipose tissue, pig heart, 
mouse preputial gland, monkey lung tissue and chick neural 
retina (Ockner and Manning, 1974; Haunerland, £t al., 1984;
Matsushita et al., 1977; Haq et al., 1982; Fournier et al.,
1983; Moore and Snyder, 1982; Haq et al., 1983 and Lee and 
Wiggert, 1984). An inter-tissue and inter species difference in 
the FABPs isolated has been observed by both immunological and 
electrophoretic methods (Said and Schulz, 1984; Glatz et al., 
1985a; Jagschies et al., 1985 and Lowe et al., 1985). FABPs are 
usually isolated from the cytosolic fractions of test tissues. 
Interestingly, intestinal FABP was found in significantly 
greater quantities in the proximal and middle thirds of 
jejuno-ileum as opposed to distal third or duodenum. In 
addition, FABP concentration in the villi was almost three times 
that in the crypts thus suggesting that cellular location is 
related to function (Ockner and Manning, 1984).
The primary translation product of rat intestinal FABP mRNA has 
been found to contain 132 amino acids (estimated molecular 
weight of 15,062 Daltons), (Alpers et al. , .1984). No
carbohydrate or lipid moieties have been observed (Haunerland et 
al., 1984). Secondary structure predictions indicated that
a-helical structure is limited to the NH2-terminal end. FABP 
is generally considered to possess only one fatty acid binding 
site per protein molecule (Glatz and Veerkamp, 1983). However, 
Haunerland et al., (1984) have reported the binding of two moles 
of oleic acid per mole purified bovine liver FABP.
A diurnal variation of FABP levels in rat liver and intestine 
has been reported (Glatz et al., 1984). However, in the case of 
the liver this has been disputed by Bass (1985a). Modulation of 
the rates of fatty acid uptake and utilization, in the 
intestine, in response to nutritional, hormonal and 
pharmacological manipulation correlated with changes in 
cytosolic content of FABP (Ockner et al., 1979; 1980; Rustow et 
al., 1982; Kawashima et al., 1982 and Brandes and Arad, 1983).
These factors are believed to be more important than photoperiod 
in diurnal variations of FABP levels. In addition Ockner et al., 
(1979) observed sex related differences in hepatic FABP levels
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(44% higher in females). Subsequent studies have indicated that 
this difference is related to sex hormonal differences (Ockner 
et al., 1980). Bass et al., (1985) found that the higher FABP
concentrations in females was associated with greater quantities 
of mRNA in the cell. They concluded that sex differences in 
hepatic fatty acid metabolism was associated with changes in 
FABP synthesis, mediated pre-translationally.
An exact role for FABP, regardless of origin, remains undefined. 
However, the bulk of the evidence available would appear to 
indicate that its role is quite general and relates primarily to 
fatty acid transport and metabolism. The cellular location of 
intestinal FABP and its concentration shifts, in response to 
changes in diet, appears to indicate an important role in fatty 
acid uptake and transport. FABP preparations have also been 
shown to modulate the activities of many enzymes for which long 
chain fatty acids are either substrates or inhibitors (Glatz et 
al., 1985). Bass et al., (1984) postulated a role for brain
FABP. They suggested that soluble FABPs in the brain act as 
regulators of synaptosomal Na+-dependent amino acid uptake by 
sequestering free fatty acids which are inhibitors of this 
process.
1.1.6 Sterol Carrier Protei^
SCP2 isolated from rat liver (Srikantaiah et al., 1976) is heat 
stable up to 55°C. It is a single polypeptide with an 
estimated molecular weight of 13,500 Daltons (determined by by 
polyacrylamide gel electrophoresis). Amino acid analysis has 
revealed that it is composed of 122 amino acids one of which is 
tryptophan (Table 1.1). Active SCP2 has been recovered from 
gels following polyacrylamide gel electrophoresis (Noland et 
al., 1980). SCP2 has also been recovered from rat adrenal 
cortical cells, luteinized rat ovaries and bovine livers 
(Vahouny et al., 1985; Tanaka et al., 1984 and Scallen et al., 
1985) . The activation of microsomal conversion of
7-dehydro-cholesterol to cholesterol has been used to 
assay individual fractions during the purification of hepatic 
SCP2.
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A role in cholesterol esterification has been reported (Gavey et 
al., 1981). Lidstrom-Olsson and Wikvall (1986) recently reported 
that SCP2 was functional in the activation of microsomal 
enzymes involved in bile acid synthesis from cholesterol. They 
concluded that SCP2 facilitated the introduction of less polar 
substrates in bile acid biosynthesis to membrane bound enzymes 
in crude systems in vitro. . However, the broad ligand
specificity of SCP2 appears not to be consistent with a 
specific regulatory function in bile acid synthesis. Vahouny et 
al., (1985) reported that SCP2 facilitated the transfer of
cholesterol from outer to inner mitochondrial membrane in the 
adrenal. However, while this transfer facilitated adrenal 
steroidogenesis, it was shown that cardiolipin was the more 
important activator of the cytochrome P450 side chain cleavage 
(P45OSCC) system of adrenal steroidogenesis.
1.1.7 Sterol Carrier Protein
1.1.7.1 Discovery
Early studies to elucidate the mechanism of cholesterol 
biosynthesis, by microsomal enzymes, revealed that an unknown 
protein factor was necessary for enzymic activity (Dempsey et 
al., 1964). By 1969, Dempsey had determined that this protein 
factor was present in the 105,000g supernatant of rat liver 
homogenate. Later studies revealed that two proteins were 
required with molecular weights of 30,000 - 60,000 and 14,000-
16.000 Daltons. At this stage it was postulated that the former 
was an aggregate of the latter lower molecular weight protein 
which was called squalene and sterol carrier protein (SCP) by 
Ritter and Dempsey (1971). This protein is the subject of the 
present thesis. In 1973 Ritter and Dempsey demonstrated the 
absolute requirement for SCP in cholesterol biosynthesis by the 
use of a purified microsomal enzyme system. Subsequent studies 
revealed that the small 'aggregates' of SCP were, in fact, a
47.000 Dalton single polypeptide called Sterol Carrier Protein^, 
(SCP]_) , (Noland et al. , 1980) . The protein described by Ferguson
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and Bloch (1977) and called Supernatant Protein Factor (SPF) is 
thought to be identical to SCP]_, both having been reported to 
function in the two-step conversion of squalene to lanosterol 
(Caras and Bloch, 1979, and Scallen et al., 1985). Scallen et 
al., (1985) have suggested that differences in the purification 
procedures may result in differences in binding specificity 
observed in vitro.
1.1.7.2 Structure and Occurrence
Molecular weight determinations of SCP carried out following 
single band migration on polyacrylamide gels in the presence of 
SDS indicated that the molecular weight is approximately 16,000 
Daltons (Dempsey, 1984). Subsequent studies using cloned cDNA 
sequences have yielded information about the amino acid sequence 
and consequently the molecular weight has been more accurately 
determined as being 14,184 Daltons. It has a pi of 7.0 
(Takahashi at al., 1982a; Dempsey, 1985). Chemical and cloned 
cDNA studies, which have been possible because of the abundance 
of rat liver mRNA, for SCP have shown that SCP is a single 
polypeptide chain of 127 amino acids whose amino-terminal 
methionine is acylated (Dempsey, 1985) . (Amino acid composition 
is detailed in Table 1.1). The absence of tryptophan in SCP is 
of interest because (i) its absence 1 causes the unusual 
diagnostic ultra-violet absorption spectrum of SCP with an 
absorption maximum of 278 nm (Dempsey et al., 1981); and (ii) it 
is also absent from the proteins FABP (Gordon et al., 1983),
Protein A (Ketterer et al., 1976) and Z-protein (Takahashi et
al., 1982) all of which have fatty acid binding properties. 
This latter point may be significant in attempting to relate 
this family of proteins. In this regard Table 1.1 shows up a 
striking similarity in the amino acid composition of SCP 
(Dempsey et al., 1981); FABP (Gordon et al., 1983); Protein A 
(Ketterer et al., 1976) and Z-protein (Takahashi et al., 1982). 
There is also a striking similarity between the amino acid 
composition of DEAE Peak I (Dempsey et al., 1981) and SCP2
(Noland et al., 1980), (ns L-TP shows some resemblence to this 
group of proteins (Poorthuis et al., 1981) though not as clear
cut). CRBP and CRABP seem to belong to a different group of
proteins.
Secondary structure predictions have indicated that a high 
proportion of SCP is helical in nature (approximately 40% 
a-helix) (Dempsey, 1985). Other studies revealed that the 
single free sulphydryl group is partially buried in the native 
molecule and is not required for functional activity with 
membrane bound enzymes catalysing cholesterol synthesis (Dempsey 
et al., 1981). SCP was found to have no associated
carbohydrate, phosphate, amino sugar or sterol moieties (Dempsey 
et al., 1981). However, SCP has approximately one mole of 
tightly or covalently bound long chain fatty acid (e.g. 
palmitic and stearic acid) per mole of protein (Dempsey, 1985). 
Interestingly no carbohydrate or lipid moieties have been 
reported in structural studies of FABP either (Haunerland et 
al., 1984).
The presence of SCP in rat liver was first noted by Dempsey et 
al., (1964). Subsequently it was isolated and purified from 
most rat tissues. It is especially abundant in tissues which 
are active in metabolism (as is true for FABP and Z-protein)
e.g. intestine, liver, adrenal, ovary and cardiac muscle. It
was also found in kidney, lung, brain, spleen, testes, skeletal 
muscle, adipose tissue and serum. In the latter it is a very 
minor component comprising only 0.4% and 0.1% of total serum 
protein during the dark and light period, respectively
(Dempsey, 1984). It has been reported that SCP is present at
higher levels (30% higher) in female rat tissues as compared to 
their male counterparts (Ockner et al., 1982; McGuire et al.,
1984). ,Sex related differences in ns L-TP and FABP levels have 
also been observed (the concentration of ns L-TP and FABP being 
50% and 44% higher respectively, in female rat gonads and 
liver, (van Noort et al., 1986 and Ockner et al., 1979).
SCP has also been obtained from a variety of other mammalian 
tissues. Among these are human liver, serum, brain, kidney, 
leukocytes and tumours, bovine liver and adrenal and mouse 
livers. Other lower forms of life have also been found to 
contain SCP. These include protozoa, yeasts, fungi and bacteria,
thus confirming the ubiquitous nature of SCP. It has also been 
isolated from a number of cell culture systems, e.g. human
fibroblasts, rat hepatocytes, mouse macrophages, Chinese hamster 
ovary fibroblasts, 3T3 adipocytes, mouse cells and many
human and mouse malignant cell lines (Dempsey et al., 1982;
Alley et al., 1982). Both ns .L-TP and Z-protein have been 
isolated from hepatoma cell culture systems (van Amerongen et
al., 1985 and Grinstead et al., 1983).
The structure and amino acid composition of SCP is remarkably 
conserved throughout nature. Human liver SCP is very similar to 
that of rat liver (Table 1.2). Similarly the amino acid
composition of yeast SCP (177 amino acids) exhibits a strong 
similarity to liver SCP, with the exception of a higher
abundance of glycine and proline. The strong structural
similarities exhibited by SCPs of different sources suggest that 
they may have diverged from a common ancestral gene (Takahashi 
et al., 1982).
Studies to determine the subcellular distribution of SCP have 
revealed that 60% is associated with the cytosolic and 30-35%
with the mitochondrial fractions of rat liver and adrenal cells 
(Conneely et al., 1984). No SCP is present in the microsomal 
fraction (Dempsey et al., 1982). The remainder (approximately
5%) is associated with the nuclear fraction. With respect to
cardiac tissues, SCP appears to be evenly distributed between 
the cytosolic and mitochondrial fractions. Conneely et al., 
(1986) have reported that nearly all mitochondrial SCP is 
present in the inner mitochondrial membrane. Very little has
been reported about the subcellular distribution of the other 
binding proteins. It appears that, in general, their cellular 
and subcellular location is strongly related to their 
biological functions.
As mentioned earlier, SCP has been found in low concentrations 
in serum. Most of this SCP was found to be associated with the 
serum lipoprotein (Dempsey, 1984a). Serum lipoproteins are the 
vehicles of transport of hydrophobic lipid molecules in the 
blood. They are complexes of lipid and protein which are divided
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TABLE 1.2 Amino Acid Composition of SCP from Different
Sources
AMINO ACID
a .
RAT LIVER
b
HUMAN LIVER
c
YEAST
Ala 2 4 13
Arg 2 2 5
Asp, Asn 11 12 20
CM-Cys 1 1 1
Glu, Gin 17 22 15
Gly 12 12 20
His 2 2 4
lieu 9 10 8
Lys 17 16 14
Met 6 3 2
Phe 6 8 10
Pro 2 2 11
Ser 6 7 12
Thr 12 12 11
Trp 0 0 0
Tyr 3 2 5
Val 12 10 16
a From cloned cDNA sequence - Dempsey, 1985.
b By amino acid analysis - Dempsey et al,, 1981.
c By amino acid analysis - Dempsey, 1984.
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into four main classes on the basis of the proportion of lipid 
and hence their density;- chylomicrons; very low density 
lipoproteins (VLDL); low density lipoproteins (LDL) and high 
density lipoproteins (HDL). The major characteristics of the 
lipoprotein density classes are shown in Table 1.3.
Studies on the distribution of serum SCP between the lipoprotein 
density classes have shown that most was associated with the HDL 
fraction (70%), while only 10% was associated with the LDL 
fraction. This finding was particularly interesting in the 
light of the now widely accepted protective role of HDL against 
atherosclerosis. The mechanism of association between SCP and 
the serum lipoproteins is as yet undetermined. The present 
study is aimed at a clarification of the lipid binding 
properties of SCP. This should shed light on the relationship 
between SCP and the serum lipoproteins. The importance of 
understanding this relationship between SCP and serum 
lipoproteins is confirmed by emerging evidence that serum SCP 
levels are elevated in individuals suffering from 
atherosclerosis (unpublished data). Progress in such 
investigations would be speeded up if a rapid sensitive method 
for quantitation of SCP was available. This study also aimed to 
set up an enzyme immunoassay for SCP.
1.1.7.3 Synthesis and Control of SCP Levels
A dramatic biphasic variation of SCP levels has been observed in 
both liver and adrenals. SCP concentrations range from 2% to 
12% of total soluble protein between the mid-light and the 
mid-dark period, respectively (Song, 1981). It seems, however, 
that cellular distribution is not affected by diurnal changes 
(Dempsey et al., 1982). McGuire et al., (1984) noted that a 
7-fold increase in SCP (i.e. from l-7mg/g of liver) occurs in 
the dark period, peaking at the mid-point and returning to basal 
levels by the beginning of the light period. A similar but 
smaller pattern of variation in SCP concentrations has been 
observed during the light cycle. A similar duirnal variation 
has been observed in studies of liver and intestinal FABP (Glatz 
et al., 1984). However, as already mentioned, Bass et al.,
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TABLE 1.3 MAJOR CLASSES OF HUMAN LIPOPROTEINS
Chylomicrons
Very Low Density 
Lipoproteins 
(VLDL)
Low-Density
Lipoproteins
(LDL)
High-Density
Lipoproteins
(HDL)
Density, g ml * <0.94 0.94 - 1.006 1.006 - 1.063 1.063 - 1.21
Particle size, nm 75 - 1,000 30 - 50 20 - 22> 75 - 10
^ Protein, % Dry Weight 1 - 2 10 25 45 - 55
Triacylglycerols, % Dry Weight 80.-95 55 - 65 10 3
Phospholipids, % Dry Weight 3 - 6 15 - 20 22 30
Cholesterol, free, % Dry Weight 1 - 3 10 8 3
Cholesterol, esterified, 7. Dry Weight 2 - 4 5 37 15
Adapted from Lehninger
(1985a) failed to observe such a variation when studying hepatic 
levels of FABP.
It was believed that the most likely level of control of SCP 
concentration was at the point of gene expression. Therefore, 
it was necessary to determine whether this control was exerted 
at the point of gene transcription (mRNA synthesis) or 
translation (manufacture of the polypeptide from mRNA). Studies 
by Dempsey et al.,(1982) revealed that changes in SCP levels, in 
liver, during the diurnal cycle were not accompanied by 
corresponding alterations in the levels of SCP mRNA. They 
concluded that regulation was occurring at the translational 
level. This was confirmed in another study by McGuire et al.,
(1984) who found that alterations in the relative synthetic 
rate of SCP accounted for the variations in SCP concentration 
in the liver and that, although large changes occurred in the 
relative synthetic rate over 24 hours, no significant changes 
were observed in the level of SCP mRNA. McGuire et al., (1984) 
suggested that the degradative rate of SCP was constant during 
the dark/light cycle. Therefore, they concluded that 
variations in SCP levels were caused by some mechanism 
controlling the efficiency of translation of SCP mRNA. 
Possible mechanisms of translational control include selective 
modification of mRNA to alter its translation; 
compartmentalization of mRNA or alteration of rates of 
initiation and elongation in different physiological states 
(McGuire et al., 1984).
By contrast, Dempsey (1984) reported that, in some rat tissues, 
e.g. brain and skeletal muscle, although the synthesis of SCP 
fluctuated during the diurnal cycle the amount of SCP did not 
change. They concluded that in these tissues variations in the 
degradative rate must have been occurring.
Studies on the mechanism of synthesis of SCP have revealed that 
it is produced as a single polypeptide of 127 amino acids. No 
pro-form of the protein is synthesized (Dempsey, 1985). This 
was unexpected as, in general, proteins which will be secreted 
from the cell are manufactured with an additional amino acid
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sequence which guides their export from the cell. This signal 
sequence is then cleaved to yield the active protein. - It seems, 
therefore, that the secretion of SCP into the serum does not
follow the regular route. It may be secreted as part of the
lipoprotein particle although this also leaves some questions 
unexplained.
Due to the fact that the relative rate of SCP synthesis
paralleled the diurnal pattern it was believed that the
photoperiod had a major influence on SCP synthesis. To
establish this a number of experiments were designed to
determine what other physiological factors (e.g. diet, hormones) 
influenced SCP levels. These studies revealed that the
photoperiod was not related to SCP levels but merely
coincidental. Stewart Hargis et al., (1986) demonstrated
clearly that both diet and hormones affected SCP levels and not 
photoperiod. They showed that after a 12-hour fast the 
diurnal cycle in SCP levels was present but Repressed, in
comparison to controls. Following a 48-hour fast the diurnal 
variation was lost but SCP levels remained at a constant high 
level throughout the 24-hour dark/light period.
As regards hormonal influences, findings indicated that upon 
glucose administration (lmg/g body weight) endogenous insulin 
secretion was increased and SCP levels increased two-fold in 
less than 30-minutes (Glatz et al., 1984). These findings
suggest that insulin is a major regulator of SCP synthesis.
However, a direct role for glucose cannot be totally discounted.
Further proofs that diet affects SCP levels, rather than 
photoperiod, have been provided by studies in which the pattern
of food intake was altered, i.e. food was given 2 or 4 hours
into the dark period. A corresponding shift in the peaking of 
SCP, as compared to control animals was observed (Stewart et 
al., 1984).
Additional studies have shown that glucocorticoids are required 
for maximum expression of insulin stimulated SCP synthesis. 
These findings also supply an explanation for why SCP levels 
decrease from the mid-point of the dark period while insulin
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levels remain high. A simultaneous decrease in glucocorticoid 
level occurs at this time (Stewart Hargis et al., 1986).
A similar dietary influence on FABP concentrations in selected 
animal tissues has been observed. Concentrations have been 
shown to be responsive to changes in the fat content of diet 
e.g. following a high fat diet the cytosolic concentrations of 
FABP also rises in chick intestine (Katongle et al., 1980) and 
in rat liver, intestine, heart and adipose tissue (Rustow et 
al. 1982; and Haq et al., 1983). Dietary linoleate was found 
to decrease both the rate of fatty acid synthesis and the 
content of FABP in rat liver (Herzberg and Rogerson, 1981). In 
addition, selected drugs have been shown to affect FABP levels. 
Clofibrate feeding in rats increases the hepatic content of 
FABP and, also, the uptake of fatty acids (Renaud et al., 
1978). Cholestyramine administration also increases the 
hepatic cytosolic FABP concentration together with the rate of 
triacylglycerol biosynthesis (Kempen et al., 1983). Thus diet 
and drug related effects are also observed in FABP 
concentration. This represents another common feature between 
SCP and FABP further indicating a strong relationship between 
these two proteins if they are not, in fact, identical.
1.1.7.4 Functions of SCP
The primary function attributed to SCP, which led to its 
discovery, is that it acts as an essential component in the 
microsomal enzymic conversion of lanosterol to cholesterol. It 
has been postulated that the mechanism of action of SCP, in 
cholesterol biosynthesis, is by initial formation of a sterol 
precursor - SCP complex which contains a number of SCP molecules 
and has particle weight of approximately 2 .5 x 10  ^ - 2 x 10® 
Daltons. This complex binds with a specific microsomal enzyme. 
The sterol precursor in the complex is converted to its product. 
The resulting sterol-SCP complex then combines with the next 
microsomal enzyme in the sequence leading to cholesterol 
synthesis. This process continues until, finally, a 
cholesterol-SCP complex results (Dempsey, 1974). This 
hypothesis is based on the ability of SCP to bind cholesterol
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and other sterols which will be discussed later. Scallen et 
al. , (1985) suggest that it is SCP2 which is important in 
conversion of lanosterol to cholesterol while Dempsey et al., 
(1981) argue that SCP2 is, in fact, the same protein as that 
which they call DEAE Protein I (Table 1.1) and amino acid 
sequencing data would seem to support this belief.
Cholesterol is a precursor of the bile acids, the major ones 
being cholic and chenodeoxy cholic acids. Consequently, studies 
were performed to determine by what mechanism the water 
insoluble intermediates of these synthetic reactions were 
transported along a series of enzymes in the hepatocyte. Some 
mechanism had to exist to solubilize the sterols and it was, 
therefore, postulated that some carrier proteins might function 
in that respect.
Initial studies by Grabowski et al., (1976) revealed that heat 
stable protein(s) from the 105,000g rat liver supernatant 
fraction, bound the bile acid precursor 7a-hydroxy-4- 
cholesten-3-one and that its conversion to 7, 12a -
dihydroxy-4-cholesten-3-one by 12a - hydroxylase was
increased in the presence of this protein or proteins. They 
found that SCP bound several water insoluble precursors of bile 
acids including 7a-hydroxy-4-cholesten-3-one and increased the 
apparent activity of 12 a hydroxylase. This finding was not 
restricted to SCP, in fact rat serum albumin was found to have 
a similar effect. While these findings do not indicate a 
unique role for SCP in bile acid synthesis they do suggest that 
a role for SCP in bile acid synthesis could exist. A role in 
extra-cellular transport of bile acids has been ruled out 
because SCP has not been found to bind cholic or 
chenodeoxycholic acids (Grabowski et al., 1976). No role in 
bile acid synthesis has been reported for the binding proteins 
most similar to SCP (i.e. FABP, Z-protein and ns L-TP). A 
role for SCP2 in bile acid synthesis has been postulated but 
until SCP2 can be shown to be pure and distinct from SCP, the 
value of these suggestions remains doubtful.
SCP is not synthesised in the adrenals (Dempsey e_t al. , 1984)
20
but it is found in high concentrations there. Therefore, it 
would seem reasonable to postulate that SCP also plays a role in 
adrenal metabolism. Ritter and Dempsey (1971) have demonstrated 
that SCP has an affinity for pregnenolone. On the basis of 
these binding studies it has been suggested that a cholesterol - 
SCP complex may participate in -the initial stages of steroid 
hormone biogenesis in adrenals. An adrenal enzyme, which 
catalyses the conversion of cholesterol to pregnenolone, was 
found to have enhanced activity in the presence of partially 
purified liver SCP prepartions (Kan et al., 1972). Similar
effects were observed, by the same authors, with a highly 
purified liver SCP complex. It was also shown that in response 
to corticotropin (ACTH), (a hormone which stimulates 
steroidogenesis in adrenal cortical tissue), SCP uptake, from 
circulating plasma, was enhanced and simultaneously, transport 
of cholesterol to the inner mitochondrial membrane occurs.
The conversion of cholesterol to pregnenolone is catalysed by 
the cytochrome P450 cholesterol side chain cleavage (CSCC) 
system located in the inner mitochondrial membrane. Studies 
indicate that enhanced transport of cholesterol to the 
cytochrome P45OCSCC system accounts, at least in part, for 
the increase in steroid synthesis in response to ACTH (Dempsey 
et al., 1980). The role for SCP in adrenal steroidogenesis 
would thus appear to be related to the transport of cholesterol 
from the cytosol to the inner mitochondrial membrane where 
steroid biogenesis occurs.
A role in steriodogenesis for Z-protein, Protein A and FABP has 
not been postulated. However, Vahouny et al., (1985) did
postulate such a role for SCP2 but suggested that the observed 
effect of SCP2 was more likely to be related to activation of 
the cytochrome P45OCSCC system by cardiolipin than to any 
direct effect by SCP2 . van Noort et al., (1986) did report 
that the ns L-TP played a role in the regulation of 
steroidogenesis by regulation of the availability of cholesterol 
to the cytochrome P45OCSCC system - a role which is, in fact, 
very similar to that postulated for SCP. This is another common 
factor linking these proteins which may be indicative that they
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are, in fact, identical. However, these data may also be 
interpreted as suggesting a relationship between the proteins 
identified as SCP2 and ns L-TP which might find support in 
similarities of their primary structures.
To carry out many of the functions ascribed to it, SCP must be 
able to bind cholesterol and several other steroids. Ritter and 
Dempsey (1973) reported binding of cholesterol, its esters and 
numerous free fatty acids by partially purified preparations of 
SCP following a series of gel filtration experiments. However, 
Scallen et al (1985) were unable to demonstrate any sterol 
binding by FABP (a protein which, they suggest and has been 
shown here, may be identical to SCP). Both, Dempsey et al., 
(1981) and Gordon et al., (1983) have reported that SCP has a 
high affinity for long chain fatty acids and consider it to 
function also as an intracellular fatty acid carrier protein. 
Others have reported that SCP specifically activates membrane 
bound enzymes catalyzing long chain fatty acid metabolism. 
Examples of such enzymes include fatty acyl-CoA ligase and 
acyl-CoA cholesterol acyltransferase (ACAT) (Daum and Dempsey, 
1980). In addition, marked correlations have been observed 
between SCP levels and rates of fatty acid uptake and 
utilization for triglycerides and phospholipid during several 
physiological manipulations (Mishkin et al., 1975 and Ockner et 
al., 1979).
Thus there is much less controversy over the fatty acid binding 
role of SCP, a feature it has in common with many of the other 
structurally similar proteins previously mentioned. A role in 
fatty acid metabolism and transport has also been postulated for 
FABP, Z-protein and ns L-TP (Glatz and Veerkamp, 1984; 
Grinstead et al., 1983 and van Amerongan et al., 1984). It
is thus necessary to establish whether SCP is strictly a fatty 
acid binding protein or if it can also bind sterols, the latter 
being an important part in its postulated role in 
steroidogenesis. Hence, this study was undertaken in an 
attempt to clarify previous reported findings.
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1.2.1 Assay of SCP Concentration.
In all of the studies to date one of two assay systems has been 
used to estimate the concentration of SCP present. The first of 
these is a spectrophotometric method based on the activation of 
membranes bound $ - sterol A^  - dehydrogenase by SCP. In 
this assay the conversion of A7 - cholestenol to A^  ’ ^ 
cholestadienol by A7 * sterol A - dehydrogenase, in the 
presence or absence of SCP (in the microsomal fraction), is 
determined by scanning the reaction mixture from 250 nm to 310 
nm. The amount of A5, 7 * cholestadienol synthesized is then 
determined from the e - 11.8 m cm"-*- for A 7 -
cholestadienol (in cyclohexane) at 281.5 nm. A unit of SCP 
activity is the increase over the microsomal fraction without 
SCP of 1 nmol of A - cholestadienol in 45 minutes 
(Dempsey et al., 1981) .
The second method which has been used in most of the 
investigations into the roles played by SCP, is an
immunoprecipitation assay. This is based on the use of a
polyclonal antibody to rat SCP, raised in rabbits (McGuire et 
al., 1984). In this assay the amount ' of immunoprecipitated 
protein in various homogenate concentrations is determined and 
plotted against total protein. The amount of SCP is estimated 
by comparison of the initial linear slope obtained against a 
plot for homogenous SCP.
Although these assays have performed well in the past, a more 
rapid and more sensitive assay would undoubtedly expedite
progress in our knowledge of SCP. To this end, this study 
reports the production of specific polyclonal antisera to SCP 
and the demonstration of their usefulness in the establishment 
of an enzyme linked immuno sorbent assay (ELISA) for SCP.
1.2. Assay Systems.
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1.2.2 Immunoassays
Immunoassays have been developed as a result of the recognition 
of the ability of all vertebrates to produce antibodies to any 
substance (immunogen) which is foreign, or perceived to be 
•foreign, by the individual animal. An antibody having been 
produced can then be used in a number of different assay' 
formats to determine antigen concentrations in unknown samples. 
Among the most widely used assays are Immunoprecipitation; 
Immunoelectrophoresis, Radioimmunoassays (RIA) and Enzyme Immuno 
Assays (EIA).
Precipitin assays are based on the fact that when antigen and 
antibody are present at a certain ratio (equivalence point) 
bridges form between antigen and antibody. This results in a
3-dimensional network which is insoluble and in agarose gels 
manifests itself as an opaque precipitate. Precipitin assays, 
on gels, include single immuno-diffusion (Mancini technique) and 
double immuno-diffusion (Ouchterlony technique). These methods 
can best be used to give qualitative information in the 
detection and identification of antibodies. The precipitin test 
has been used in a quantitative manner by estimating the protein 
content of the precipitate at optimal proportions. However, 
there are drawbacks to this method when 'dealing with samples 
which contain unknown antigen concentrations as maximum 
precipitation occurs only at the equivalence point. In addition 
large quantities of both antibody and antigen are required 
rendering such assays unsuitable for detection of minute 
quantities of antigen in unknown samples.
Immunoelectrophoresis is a modification of immuno-precipitation. 
The reaction of antigen and antibody occurs in a solid phase 
(agar gel) but is speeded up by the application of an electric 
field. The antibody is incorporated into the gel while the 
antigen is applied to a well. Under the influence of the 
electric field the antigen migrates to the antibody. Again this 
system is more suited to yielding qualitative rather than 
quantitative information about the test antibodies.
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RIAs were initially developed by Yalow and Berson in 1960. The 
basis of the technique is the use of a saturable binding agent 
(antibody) present in restricted quantities to which a 
radiolabelled antigen can bind. The introduction of unlabelled 
antigen by comparative inhibition, reduces the amount of 
labelled antigen which binds to a degree relative' to the 
concentration of unlabelled antigen. This technique has a very 
high level of sensitivity and reproducibility and has, 
therefore, gained widespread use. However, there are a number 
of drawbacks including the high cost of isotopes and their short 
shelf life; complex equipment is required for the determination 
of results and, finally, a strong awareness of the dangers 
associated with widespread use of isotopes and their subsequent 
disposal. As an alternative, other methods of antigen labelling 
have been found which include use of enzymes, free radicals, 
bacterial phages and fluorescent markers. These latter methods 
have begun to replace the use.of RIAs in recent times.
EIAs can be subdivided into homogenous and heterogenous enzyme 
immunoassays. In the former a hapten is linked to an enzyme in 
such a manner that the enzyme is altered when the hapten
combines with the antibody. This enzyme alteration is
manifested spectrophotometrically following addition of a 
suitable substrate. In the latter system a separation step is
performed where the reacted enzyme labelled component is 
separated, by washing, from the unreacted enzyme labelled 
material. Heterogenous EIAs have been further refined by 
linkage of soluble antigen or antibody to a solid phase to
facilitate the separation step. This modification is termed an 
Enzyme Linked Immuno Sorbent Assay (ELISA).
A number of ELISA systems exist including a competitive 
inhibition assay and a sandwich assay. In the former a limited 
quantity of the appropriate antibody is initially bound to the 
solid phase. A limited amount of enzyme-labelled antigen is 
then added along with the sample or standard unlabelled antigen. 
As with RIA the amount of unlabelled antigen binding to the 
antibody reduces, by competitive inhibition, the binding of the
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labelled antigen to a degree which is dependent on the 
concentration of the unlabelled antigen in the sample.
The sandwich assay system is a multi-tier system where either 
antibody or antigen can be initially bound to-the solid phase. 
If the antigen is bound to the solid phase, it is then reacted 
with the appropriate antibody which may be labelled itself or 
may in turn be reacted with an enzyme-labelled second antibody. 
This assay design is more suited to the estimation of specific 
antibody concentration than to antigen estimation. Only a 
proportion of the protein present binds to the solid phase
during the coating step and thus the sensitivity of antigen 
estimation would be low. The double antibody sandwich ELISA is 
more suitable for measuring antigen concentrations. In this 
system an antibody is initially adsorbed to the plate. The
excess is washed away following a suitable incubation period. 
The antigen containing solution is then added and, again, 
following a suitable incubation time, the plate is washed. Next 
an enzyme labelled specific antibody is added, incubated and the 
plate subsequently washed. Finally, enzyme substrate is added 
and the subsequent colour reaction observed
spectrophotometrically, is proportional to the antigen 
concentration in the sample solution. However, this assay 
format requires two specific antisera ' for the antigen in
question. The same antiserum would be unlikely to work
especially with relatively small antigens (as SCP), which might 
be expected to have fewer antigenic determinants.
1.3 Aims of This Thesis
The aims of this thesis are therefore:
(i) to isolate and purify SCP from rat liver;
(ii) to clarify some of the lipid binding properties of the 
pure protein and 
(iii) to carry out the preliminary steps in the development of 
a sensitive ELISA assay system for SCP which would permit 
its rapid measurement in serum and other biological 
samples.
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MATERIALS AND METHODS
2.1 MATERIALS
2.1.1 Chemicals
Chemicals used for routine laboratory procedures were of AnalaR 
or analytical grade, unless otherwise stated. General 
laboratory chemicals were obtained from BDH Chemicals Ltd., 
Poole, England and Riedal de Haen AG, Hannover, Germany. 
Bradford reagent was from Bio-Rad Laboratories, Germany. 
Spectrapor membrane tubing was from Spectrum Medical Industries 
Inc., U.S.A. Ultra-filtration membranes were from the Amicon 
Corporation, U.S.A. Santillation grade toluene was from Labscan 
Ltd., Ireland. Scintillation grade 2,5-diphenyloxazole was from 
Koch Ltd., Suffolk, England. Radiochemicals were from Amersham 
International pic., England. All antibodies and immunochemical 
reagents were obtained from Sigma Chemical Company, England. 
Complete and incomplete Freunds adjuvants were from Gibco 
Laboratories, U.S.A. All column packing materials were supplied 
by Pharmaci,a Fine Chemicals, Uppsala, Sweden.
2.1.2 Research Animals
2.1.2.1 Source and Strain
Rats used for isolation of protein were female Wistar rats and 
were supplied by Ballina Laboratories, Ireland. Rabbits used 
for immunization were female New Zealand Whites and were 
supplied by Ballina Laboratories or Becton-Dickenson, Dublin, 
Ireland. Female Balb C mice were also used for immunization 
studies and were bred in our own animal houses.
2.1.2.2 Animal Maintenance
All animals were maintained under standard conditions of 
lighting and heating, 12-hours light and 12-hours dark and at 
21°C respectively, unless otherwise stated. All received 
standard animal foods:- rabbit pellet supplied by Paul and 
Vincent, Ireland in the case of rabbits and Sow Breeder Nuts 
from Liam Connolly and Sons Ltd., Ireland in the case of the
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rats and mice. All animals were routinely sacrificed upon 
completion of experiments.
2.2 METHODS
2.2.1 Purification of Sterol Carrier Protein
Purification of SCP was performed at 4°C by the method of 
Dempsey et al., (1981), unless otherwise stated. Deionized 
distilled water was used in preparation of all buffers used. 
0.1% sodium azide was utilized in all solutions as an 
antibacterial agent, unless otherwise stated. All glassware used 
during purification was coated in polyethylene glycol 20,000 
(Kramer et al., 1976).
2.2.1.1 Protein Extraction
Female Wistar rats, approximately 200-250g in weight, were 
maintained under conditions of constant light (to increase SCP 
levels, Dempsey, 1984) for 3- to 4- days prior to being 
sacrificed by stunning and exsanguination. The livers were 
excised and stored in ice-cold 0.2M phosphate buffer, pH 7.4, 
prior to homogenization. These were weighed and placed in fresh 
phosphate buffer (2ml/g of liver). The liver was homogenized 
using a 15 ml Dounce Tissue Grinder. The, resultant homogenate 
was centrifuged at 5,000 rpm for 15-minutes in a refridgerated 
bench centrifuge. The supernatant from this step was 
centrifuged at 105,000g for 90 minutes in a Beckmann 
ultra-centrifuge. The supernatant (cytosol) obtained from this 
step was filtered through glass wool to remove any traces of fat 
and then stored at -20°C until required.
2.2.1.2 Gel Filtration
10-15 ml of rat liver cytosol was applied to a Sephadex G-75 
column which was equilibrated with 30 mM Tris/HCl buffer, pH 
9.0. Sample was eluted at a flow rate of 36 ml/hr. 3 ml 
fractions were collected and protein content monitored by 
reading the absorbance at 280 nm. Fractions comprising the 
second protein peak (G-75 Peak II) were pooled and stored at 
-20°C prior to ion-exchange chromatography.
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2 .2 .1.3 DEAE - Cellulose Chromatography
The DEAE-cellulose column was equilibrated with 30 mM Tris/HCl 
buffer, pH 9.0, prior to sample application. 150 ml of the 
second protein peak, obtained from the gel filtration procedure, 
was applied and eluted at a flow rate of 330 ml/hr. Fractions 
(3 ml) were routinely monitored for protein content by reading 
the absorbance at 280 nm. The first peak (DEAE - Peak I) having 
been eluted, the mobile phase was changed to 30 mM Tris/HCl 
buffer, pH 9.0, containing 64 mM NaCl. This buffer was used as 
the mobile phase until the second peak (DEAE-Peak II) was 
completely eluted. Fractions comprising each peak were pooled 
and stored, separately, at -20°C prior to protein 
determination and subsequent preparation for gel 
electrophoresis.
2.2.1.4 Protein Determination
Protein concentration of all samples was determined using the 
method of Lowry et al., (1951). A standard curve was prepared 
using bovine serum albumin (BSA) ranging from 0 - 2.0 mg/ml. 
Distilled water was used to blank the spectrophotometer prior to 
reading of all absorbances.
2.2.1.5 Dialysis and Concentration of SCP
To render the protein suitable for gel electrophoresis, binding 
studies and enzyme immunoassays a dialysis step was required. 
Dialysis Tubing from Spectraphor, with a molecular weight cut 
off of 5,000 Daltons was used. This very low molecular weight
cut off tubing was used as problems were encountered when using 
an Amicon ultra-filtration unit where the low molecular weight 
cut off filters were not found to be effective in concentrating 
the SCP samples. Routinely 100 ml of DEAE-Peak I and DEAE-Peak 
II proteins were dialysed against 4 litres of deionized 
distilled water for 24-hours. Samples for polyacrylamide gel 
electrophoresis were concentrated by coating the tubing with 
polyethylene glycol 20,000 and then freeze dried in aliquots. 
No further concentration step was required for the SCP being 
used in the binding and enzyme immunoassays.
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2.2.1.6 Polyacrylamide Gradient Gel Electrophoresis
Linear gradients of polyacrylamide, 5-35%, were cast in slab 
moulds. The moulds consisted of glass plates 14 x 8 cm 
separated by 2.7 mm spacers. The gradient-gel making apparatus 
and linear gradient maker are depicted in Figure 2.1. Both were 
supplied by Pharmacia.
2.2.1.6.1 Casting of Gels
Gels were cast by placing 35% (w/v) acrylamide solution, made up 
in gel buffer - 88.7 mM Tris/81.5 mM boric acid/2.5 M disodium 
EDTA/0.025% sodium azide, pH 8.3, in Vessel A (Figure 2.1). Gel 
buffer alone was placed in Vessel B both solutions having 
previously been degassed. 2.5 ml of initiator (10% (w/v)
ammonium persulphate) was added per 100 ml of each solution and 
100 *j1 of 5% (v/v) TEMED was added to each vessel per 100 ml of
each solution. Initially an overlay solution, 5% (v/v)
methanol, was introduced into the casting chamber. The
connection between Vessels A and B was opened and the first 
portion of the gradient corresponding to 0-5% acrylamide was 
collected and discarded. The volume discarded was dependent on 
the number of gels being cast. The remainder of the gradient 
was then introduced into the casting chamber followed by the 
underlay solution, 1.0 M sucrose coloured with bromophenol blue. 
The gels were left to polymerize and then removed and stored 
under gel buffer at 4°C until required.
2.2.1.6.2 Sample Preparation
Freeze-dried protein samples were reconstituted in sample buffer 
- 8.87 mM Tris/8.15 mM boric acid/0.25 mM sodium EDTA/5% (v/v) 
2-mercaptoethanol/2.0% (w/v) SDS/10% (w/v) sucrose, pH 8.3
(coloured by bromophenol blue to enhance visualization) - to a 
protein concentration of 3 mg/ml. Samples were solubilized by 
heating, in sample buffer, to 100°C for 5-minutes.
2.2.1.6.3 Running Conditions
The gels were run in Pharmacia electrophoresis apparatus GE 
2/4, using an LKB 2197 Power Supply. The running buffer used
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Figure 2.1 Linear gradient
Casting Chamber
3-way valve
maker and gradient gel casting apparatus
was the gel buffer, pH 8.3, with 0.1% SDS. Prior to sample 
application the gels were pre-run at 150 V for 30-minutes to 
allow equilibration between the gels and the running buffer. 
Samples including a set of low molecular weight markers, 
supplied by Pharmacia, were then applied to the gels, 50jjl and 
10 j^l respectively, and the voltage increased to 300 V until the 
samples entered the gel (approximately 10 minutes). The voltage 
was then reduced to 100 V and electrophoresis continued for 12 
hours.
2.2.1.6.4 Staining of Gels
The gels were fixed for a minimum of 1 hour in a 15% (w/v) TCA 
solution. They were stained with a 0.2% (w/v) solution of PAGE 
blue-83 in water/methanol/acetic acid (6 : 3 : 1, by volume) for 
24 hours at room temperature. Gels were then destained in 
water/methanol/acetic acid ( 6 : 3 : 1 ,  by volume) until the 
background was clear. The gels were stored in destaining 
solution until the SCP bands were removed for immunization.
2.2.1.6.5 Molecular Weight Determinations
The molecular weights of DEAE-Peak I and DEAE-Peak II proteins 
were determined by comparison of their electrophoretic 
mobilities with those of the protein standards supplied by 
Pharmacia, mentioned earlier (2.2.2.6.3.). This was possible 
because the electrophoretic mobility of a protein subunit on SDS 
polyacrylamide gradient gels is related to its molecular weight 
(M.W.) by the following equation.
Mobility a L°gl0 M-w*
2.2.2 Cholesterol and Fatty Acid Binding by SCP
A number of different methods were utilized to establish some of 
the binding properties of the purified SCP. The chosen ligands 
for study were cholesterol and oleic acid, both of which were 
labelled with tritium.
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2.2.2.1 Preparation of [^ H] - cholesterol solutions
Three different preparations of [^ H] - cholesterol were used 
during these studies.
Firstly a solution with an intended concentration of 300 nmol 
cholesterol/ml and a specific activity of 5mCi/nmol was used in 
the Lipidex 1000 studies. The specific activity was obtained by 
dilution of the labelled cholesterol (9. 6Ci/nimol) with 
unlabelled cholesterol. The appropriate volumes of labelled and 
unlabelled cholesterol in inorganic solutions were combined, the 
solvent evaporated under N2 and the cholesterol redissolved in 
10 mis 30mm Tris/HCl buffer (pH 9.0) by sonication for 4 by 1 
minute intervals. It soon became apparent that the above 
solution had a lower concentration than was intended. The 
reported solubility of cholesterol in aqueous solution at 25°C 
is 4.7 jjM or 4.7 nmol/ml (Haberland and Reynolds 1973). 
Therefore, this was presumed to be the concentration of the 
prepared solution. This solution was routinely further diluted 
1 in 10 before use giving a solution of 470 pmol/ml.
A solution containing 7.6 pmol cholesterol/ml with a specific 
activity of 32.9 Ci/mmol was used in the activated charcoal and 
some gel filtration experiments. The solution was prepared by 
initial dilution of labelled cholesterol 1 in 20 with toluene. 
Subsequently, an appropriate volume of the toluene solution was 
added to a glass vial, dried down and redissolved in 30mM 
Tris/HCl buffer (pH 9.0). This solution was thoroughly mixed by 
vortexing immediately prior to use.
In some experiments, which involved the use of gel filtration to 
separate bound and free cholesterol, a solution of cholestrol in 
propylene glycol was used. This solution contained 7.6pmol/ml 
with a specific activity of 32.9 Ci/mmol. This was prepared in 
a similar manner to the previous solution. All dilute solutions 
were stored at 4°C for use as required.
2.2.2.2 Preparation of [^H]-oleic acid solution
A solution of 238 pmol of Oleic acid/ml with a specific activity 
of 4.1 Ci/mmol was prepared as follows. A 1 in 20 dilution of
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the labelled oleic acid was initially made with toluene. An 
appropraite volume of this solution was dried down in a glass 
vial and redissolved in 1000 times the volume of 30 mM Tris/HCl 
buffer (pH9.0). The solution was mixed thoroughly by vortexing 
prior to use. This solution was used in all fatty acid binding 
studies.
2.2.2.3 Delipidation of SCP
For some experiments the SCP was delipidated prior to use by the 
method of Chen (1966). 0.005g of activated charcoal was added
to 100 mis of SCP (0.1 mg/ml) and the pH lowered to 3.0 by the 
dropwise addition of 0.2 M HC1. This solution was then placed 
in an ice-bath and mixed, using a magnetic stirrer for one hour. 
The charcoal was removed by centrifugation at 20,200 g for 20 
minutes in a Sorvall centrifuge with an S-34 rotor at 2°C. 
The supernatant was collected and the pH brought to 7.0 by the 
dropwise addition of 0.2 M NaOH. The delipidated solution was 
stored at 4°C until required and subsequently concentrated, by 
reverse dialysis against polyethylene glycol 20,000 to a 
desired concentration of 0.25 ,mg/ml.
2.2.2.4 Binding Studies Using a Lipidex 1000 Column to 
Separate Bound and Free Ligand.
To prepare the Lipidex 1000 column, 0.5 g of the powder was 
allowed to swell overnight in 10 ml of methanol at 4°C. The 
solution was then degassed and a 1 ml column poured in a 2 ml 
syringe. This column was stored at 4°C for use as required 
Prior to use the column was equilibrated with 10 column volumes 
of 30 mM Tris/HCl buffer (pH 9.0) at the required running 
temperature. The flow rate was maintained at 12 ml/hr.
Initially, the ability of the column to bind free cholesterol at 
4°C and 30°C, was tested. 300jjl of a cholesterol solution 
(with a concentration of 470 pmol/ml) in 30 mM Tris/HCl buffer 
(pH 9.0) was applied to the column and 0.5 ml fractions 
collected. The unbound cholesterol was eluted with buffer: (30 
mM Tris/HCl (pH 9.0)). Change of the mobile phase to methanol 
resulted in elution of the bound labelled material. 0.3 ml of 
each fraction was counted for radioactivity in a Beckmann
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Scintillation Counter. The scintillation cocktail used was 0.5% 
(w/v) 2,5-diphenyloxazole in a 2:1 toluene/Triton X-100
solution, 6 ml of which was used per sample. The percent label 
bound by the column was estimated by calculation of the 
percentage of total counts in the eluent comprising the second 
peak.
Protein binding activity was investigated by incubation of the 
test proteins (400jjg BSA and 8.6jjg SCP) and labelled cholesterol 
(94 pmol and 47 pmol, respectively) at 37°C for 30 minutes in 
polypropylene vials. The mixture was then applied to the 
Lipidex 1000 column and run as already described at temperatures 
of 4°C and 30°C. Fractions were monitored for radioactivity 
as described previously.
2.2.2.5 Binding Studies Using Activated Charcoal to 
Separate Bound and Free Ligand
The following charcoal suspensions were used during these 
studies:(A) 0.1% - 1% (w/v) activated (Norit A) charcoal in 0.1M 
PBS (pH 7.4); (B) Dextran coated charcoal (2.0% (w/v) charcoal, 
0.2% (w/v) Dextran T-70) in 0.1M PBS buffer (pH 7.4) with 0.1% 
(w/v) gelatin added as required.
A similar assay procedure was followed when the binding of both 
cholesterol and oleic acid by SCP and BSA was being measured 
using activated charcoal to separate bound and free ligand. The 
assay was performed in 1.5 ml polypropylene tubes. 200jjl of the 
protein solutions containing O.ljug to 100jjg of SCP or 10^g of 
BSA were incubated with 100 jjl of the labelled cholesterol 
solution in buffer at a concentration of 7.6 pmol/ml for 30 
minutes at 37°C. The final cholesterol concentration was thus
2.5 nM. The vials were then placed in a methanol bath at 0°C 
and 0.1 ml of one of the ice-cold activated charcoal
suspensions, described above, was added to separate bound and
free label. The samples were vortexed and incubated at 0°C
for 10 minutes and then centrifuged in an Eppendorf microfuge 
for 2-minutes at 10,000 g. 0.3 ml of the supernatant was 
counted for radioactivity as described previously. For the
estimation of non-specific binding the protein solution was 
replaced by buffer and a similar protocol followed.
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In the oleic acid binding studies lOjjg of protein either BSA or 
SCP in a volume of 200 pi was incubated with 100 pi of the 
labelled oleic acid solution described above. The final oleic 
acid concentration was, therefore, 79 nM.
2.2.2.6 Investigation of Gel Filtration as a means to
separate Bound and.Free Cholesterol
A number of gel filtration columns (1.4 x 20 cm) were prepared 
using Sephadex G-10, G-25 and G-75 by pre-swelling the
respective beads in 30 mM Tris/HCl buffer (pH 9.0), (with 0.005% 
Sodium Azide as a preservative). The solutions were degassed 
and the columns packed by elution of several column volumes of 
buffer.
All columns were stored at room temperature and used as 
required. The void volume was determined by application of 0.5 
ml of a 0.5% Blue Dextran solution to each of the columns. When 
running the columns 0.5 ml of the second and third cholesterol 
solutions mentioned earlier was added and eluted at a flow rate 
of 15 ml/hr. 0.5 ml fractions were collected and assayed for 
radioactivity as described previously.
2.2.3 Antibody Production and Characterization
Antibodies to SCP, purified in Section 1 (2.2.1) were raised in 
both mice and rabbits (Ascites production and intradermal 
injection, respectively). In both cases native SCP and SCP from 
polyacrylamide gels were used.
2.2.3.1 Production of Antibodies in Ascites Fluid in Mice
Antibody production was induced by intraperitoneal injection of 
SCP (in either the native form or in polyacrylamide gel slice) 
into two groups, each comprised of 4-mice, according to the 
procedure of Tung (1983).
Ten to twelve week old female Balb C mice were used. This age 
group was chosen because it is reported that in younger mice 
(six to eight weeks) only small volumes of ascites are produced 
and in older animals the production of ascites is reported to be
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much slower. Females were used as males of this strain tend to 
be more aggressive.
Animals were immunized with an emulsion of complete Freunds 
adjuvant and antigen in the ratio of 9 : 1. A stock solution of 
5 mg/ml native SCP was prepared following dialysis and 
concentration as described (2.2.1..5). Bands from polyacrylamide 
gradient gel electrophoresis gels corresponding to SCP were 
excised and homogenized in distilled water to a final 
concentration of 5 mg/ml PAG-incorporated SCP. Immediately 
prior to injection the emulsion was prepared, by vortexing, 
using 0.2 ml of the appropriate stock solution and 1.8 ml 
Freunds complete adjuvant.
0.2 ml of the emulsified immunogen was injected 
intraperitoneally using a 21-guage, 1.5 inch needle with a 1-ml 
syringe, into each mouse. This was day 0 of the immunization 
schedule. This step was repeated on days 14, 21, 28 and 35. In 
the interim, where ascites fluid development was visually 
apparent (by swelling of the abdomen) the fluid was collected by 
the insertion,of a sterile 18-guage, 1.5 inch hypodermic needle 
close to the surface of the peritoneal cavity. On day 42 each 
mouse was injected intraperitoneally with 0.5 ml pristane. This 
was the only occasion that pristane was used.
Following collection of the fluid the ascites was filtered 
through nylon mesh, centrifuged at 2,500 rpm for 15 minutes at 
4° C to remove cell debris. The fatty layer was removed using 
cotton tipped applicators. The ascites was recentrifuged at
15,000 rpm for 20 minutes at 4°C and the supernatant was 
filtered through glass wool to remove any remaining fat. The 
ascites was then stored at -20°C until all ascites production 
was completed.
2.2.3.2 Antibody Production in Rabbits
Antibody production was induced either by intradermal injection 
of SCP (in either native or PAG-incorporated form) or by 
sub-cutaneous injection using a 1 : 1 ratio of Freunds complete 
adjuvant to immunogen. Both methods have been reported to give 
a good immune response (Hurn and Chantler, 1978). 3-month-old
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New Zealand Whites were subjected to the immunization schedule 
as outlined in Table 2.1. The animals were bled at regular 
intervals and the serum titre for anti-SCP activity determined 
using a sandwich ELISA with commercial conjugates. Large bleeds 
were taken when appropriate, approximately 7 - 1 0  days after 
boosting.
Blood was collected from the ear vein in clean dry bottles and 
allowed to clot at room temperature. Samples were then 
centrifuged and the serum separated and stored at -20°C for 
further processing.
2.2.3.3. Enrichment for Immunoglobulin
Enrichment for immunoglobulin was performed by the method of 
Tung (1983) on the large bleed samples and pooled ascites from 
each group. Each sample was placed in a beaker on ice and 5N 
ice cold HC1 was added to adjust the pH to 4.5 - 5.1 with 
continuous stirring to precipitate the fibrinogen. This pH was 
maintained for 1 hour and the samples were then centrifuged at
15,000 rpm for 20 minutes at 4°C. The supernatants were 
collected and 5 N NaOH was added, dropwise with continuous 
stirring, to adjust the pH to 7.0 - 7.2. To enrich for
immunoglobulin 25% sodium sulphate was added dropwise to a final 
concentration of 18%. The volume of 25% sodium sulphate was 
calculated by the following formula:
18 - 25x
(x+y)
Where x = volume of 25% sodium sulphate and y = initial volume 
of sample. All steps from this stage were performed at room 
temperature. The samples were allowed to stand for 1 hour prior 
to centrifugation at 15,000 rpm for 20 minutes at 20°C. The 
resultant supernatant was discarded and the precipitates were 
washed once with 13% sodium sulphate and the centrifugation step 
repeated. The resulting pellets were suspended in a minimal 
volume of distilled water. The samples were then dialysed 
against 0.1 M Tris/HCl buffer, pH 8.0, overnight. The 
antibodies were stored at 4°C for use as required.
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TABLE 2.1 Immunization Schedule of Test Rabbits
....
Animal
Initial Immunization 1st Boost 2nd Boost
SCP aRoute
Days
Post
Initial
Immun­
ization
SCP
Days
Post
Initial
Immun­
ization
SCP aRouteNative PAG-Incorp. 
*Jg Pg
Native PAG-Incorp. 
*Jg Pg
Route Native PAG-Incorp. 
Mg V&
R262 220 I.D. 25 150 S.C. 139 150 S.C.
R263b 300 I.D. ' 25 150 S.C. - - -
R279 150 I.D. 91 75 S.C. - - -
R280 150 I.D. 91 75 S.C. - - -
R282 500 S.C. 68 • 250 S.C. - - -
R283b 360 S.C. - - - - - -
R284 500 I.D. 68 250 S.C. - - -
R289 360 I.D. 68 250 s .c . - - -
a) I.D. = intradermal injection along multiple sites (<^ 20) on the back
S.C. = subcutaneous injection using multiple sites (^4) on the back
b) = animals died of natural causes post inmunization
2 . 2 . 3.4 Antibody Titre Determination
The antibody titres of each bleed and of enriched immunoglobulin 
samples were determined. Nunc 96-well, non-sterile polystyrene 
microtitre plates were coated with 10pg of SCP per well in 200pl 
of 0.05 M Carbonate buffer, pH 9.5. The plates were incubated 
at 37°C for 1.5 hours and then washed five times with 0.1 M 
PBS/0.05% (v/v) TWEEN wash solution. The plates were dried by 
tapping of plates on tissue paper until all traces of liquid 
were removed and then 100 pi of the test sample, at increasing 
dilutions, was added. The plate was incubated at 37°C for 1.5 
hours and washed as before. A suitable dilution of a 
horse-radish peroxidase conjugated anti-rabbit or anti-mouse IgG 
(as required) was prepared in 0.1 M PBS/0.05% (v/v) TWEEN and 
150 pi added per well. The plate was then incubated at 37°C 
for 2 hours and washed again. The colour was developed by 
adding 100 pi of substrate solution (1.5 mg 0-phenylenediamine 
(OPD)/0.5 M phosphate/0.1 M citrate buffer, pH 5.0) containing 
0 .6 pi H2O2 per ml) to each well and the plates left in the 
dark at room temperature for 30 minutes. The reaction was 
stopped by the addition of 25 pi of 20% H2SO4 to each well 
and the O.D.490 ^  of each well was read, immediately using an 
ELISA EL 307 plate reader. The titre was taken as the dilution 
which gave an O.D. 490 ^  reading of 1.0 under the standard 
assay conditions.
2.2.3.5 Determination of the Specificity and Sensitivity
of the Antisera
The specificity of selected antisera was determined by coating 
wells of the microtitre plates with 100 or 1000 pg of selected 
proteins in a total volume of 200 pL as for coating of SCP. 
DEAE Peak I protein used was purified by a second passage 
through the ion-exchange column. The assay was then completed 
as described in section 2 .2 .3.4.
The sensitivity of selected antisera was determined by coating 
wells of the microtitre plate with 0.02-2 p g SCP in a total 
volume of 200 pi. The assay was then completed as described in 
section 2 .2.3.4.
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3 RESULTS,
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3.1 Purification of SCP
The purification of SCP was carried out by the method of 
Dempsey et al. , (1981) as outlined in section 2.2.1. Liver 
cytosol was initially subjected .to gel filtration on a Sephadex 
G-75 column, which has a fractionation range of 3,000 to 70,000 
molecular weight. This resulted in separation of the low
molecular weight proteins in the cytosol. A typical elution
profile is outlined in Figure 3.1.1. The lower molecular 
weight proteins were present in the second peak called 
G-75-Peak II protein. Further purification of SCP was achieved 
by DEAE-ion-exchange chromatography of the pooled fraction 
comprising G-75-Peak II proteins. SCP, having a pi of 7.1, 
bound to the anion exchanger - DEAE cellulose - at the running 
pH of 9.0 and was displaced by increasing the salt 
concentration. The elution profile resulting from this 
ion-exchange step is shown in Figure 3.1.2. Generally the 
bound protein was eluted as a single peak as described by
Dempsey et al., (1981). However, where older animals (greater 
than 6-months) were used as the source of liver cytosol a
second small peak, called DEAE-Peak Ila was obtained shortly 
after change of the mobile phase (Figure 3.1.3). No such peak 
has been reported by Dempsey et al., (1981). The major peak 
called DEAE-Peak II consistently corresponded to the position 
of the SCP peak of Dempsey et al., (1981).
The recovery of protein at each stage was determined as 
described in section 2.2.1.4 and the results outlined in Table
3.1.1. As expected most of the protein was lost in the gel 
filtration step. Greater than 80% of the protein applied to 
the ion-exchange column was routinely recovered with 21% 
appearing in DEAE-Peak I and 62% in DEAE-Peak II. Assuming 
that the protein in DEAE-Peak II is pure SCP, this means that 
2.3% of the initial protein was recovered as SCP. This 
corresponds well with the reported values of SCP being 2-8% of 
total cytosolic protein (Dempsey et al., 1981; Conneely et al., 
1984 and Dempsey, 1985).
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Figure 3.11 Sephadex G-75 chromatography of rat liver 105,000 g supernatant.
Protein profile is Illustrated by plotting O.D. 280nm Vs. fraction number.
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Figure 3.1.2 DEAE - cellulose chromatography of Sephadex G-75 Peak II protein.
Protein profile is illustrated by plotting O.D. 280nm Vs. fraction number.
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Figure 3.1.3 DEAE - cellulose chromatography of Sephadex G-75 Peak II protein
Protein profile is illustrated by plotting O.D. 280nm Vs. fraction number.
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TABLE 3.1.1 Protein content of different fractions collected 
during purification as determined by the Lowry 
method.
PURIFICATION OF RAT LIVER SCP
FRACTION VOLUME
(ml)
TOTAL PROTEIN 
(rag)
PROTEIN YIELD 
(%)
105,OOOg 
Supernatant 10 1,600 100
G-75 Peak II 
Combined Fractions 
(42-68 Fig. 3.1.1) 120 58.8 3.7
DEAE-Peak I 
Combined Fractions 
(30-68 Fig. 3.1.2) 114 12.54 ■ 0.78
DEAE-Peak II 
Combined Fractions 
(104-150 Fig. 3.1.2) 138 36.8 2.3
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The purity of the final protein peaks was checked by SDS 
polyacrylamide gradient gel electrophoresis (Figure 3.1.4). A 
sample of purified SCP (obtained as a donation from Dr. Mary 
Dempsey, Minneapolis, U.S.A.) was also run on the gel. The 
DEAE-Peak II sample, which was thought to be pure SCP, had one 
major band which co-migrated exactly with the donated SCP. 
However, a very fine band of protein (approximately 30,000 
Daltons) was also visible in the DEAE Peak II material. It was 
thought that this might be an aggregate of SCP following a 
report by Dempsey et al., (1981) that some irreversible
aggregation of SCP occurs during lyophylization. It should be 
noted however, that the donated SCP was also lyophylized prior 
to electrophoresis.
The DEAE-Peak I material showed two bands with slightly greater 
mobility than the SCP. In addition a band corresponding to 
that of SCP was also apparent in the lane comprising DEAE-Peak 
I material. This was not totally unexpected as Dempsey et al.,
(1981) reported that a low level of contamination of DEAE-Peak 
I with SCP does occur during purification and" that 
rechromatography on an ion-exchange column completely resolves 
SCP from DEAE-Peak I protein. Similar observations were made 
by this author.
The molecular weight of proteins can be determined by 
comparison of their electrophoretic mobility in SDS 
polyacrylamide gradient gels with those of protein standards of 
known molecular weight. From the resultant standard curve 
(Figure 3.1.5) the molecular weight of the donated SCP and the 
purified SCP (DEAE-Peak II protein) was determined to be 
approximately 16,400 Daltons while that of the major DEAE-Peak 
I protein was found to be approximately 13,300 Daltons. Both 
these results correlate well with reported findings of Dempsey 
et al., (1981) where the values obtained were 16,000 and 14,000 
Daltons respectively.
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FIGURE 3.1.4 polyacrylamide gradient gel electrophoresis of 
different stages of SCP purification. Lane 1: Low molecular 
weight markers; Lane 2: donated SCP; Lane 3: purified SCP 
(DEAE-Peak II); Lane 4: DEAE-Peak I; Lane 5: Sephadex G-75 
Peak II; Lane 6: 105,000g rat liver supernatent.
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Figure 3.1,5 Plot of the log of molecular weight of standard proteins against
electrophoretic mobility In polyacrylamide gradient gels. Each point 
being determined by the mean of 12 estimations.
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3.2 Studies on Cholesterol and Fatty Acid Binding by
SCP.
There is much controversy in the literature over the lipid 
binding properties of the protein known as SCP. It was thus 
decided to clarify the cholesterol and fatty acid binding 
properties of pure SCP.. To demonstrate binding of ligands by 
binding proteins an efficient means of separation of bound and 
free ligand is required. A number of methods were tested in 
this study.
3.2.1 Cholesterol Binding Studies
3.2.1.1 Studies with Lipidex 1000 as the Separating Agent
Lipidex 1000 a 10% (w/w) substituted hydroxyalkoxypropyl
derivative of Sephadex G-25 can be used to separate unbound and 
protein bound small hydrophobic molecules in a temperature 
dependent manner (Dahlberg et al., 1980). This property was 
exploited by Glatz and Veerkamp (1983) when they used Lipidex 
1000 to demonstrate fatty acid binding by proteins.
Initially studies were carried out to show that a Lipidex 1000 
column could be used to separate unbound and protein bound 
cholesterol in an aqueous solution. An aliquot of cholesterol 
solution (470 pmol/ml; 9.6 Ci/mmol) containing 141 pmol 
cholesterol was applied to a Lipidex 1000 column maintained at 
4°C or 30°C. The first peak in Figures 3.2.1.1 and 3.2.1.2 
represents the unbound cholesterol which was not retained by 
the column. This amounted to 21% and 19% of the labelled 
cholesterol applied to the column at running temperatures of 
4°C and 30°C, respectively. Hence, approximately 80% of 
the total cholesterol applied was bound at both running 
temperatures. All of the bound cholesterol could be recovered 
from the column matrix by changing the mobile phase to 
methanol. The proportion of added cholesterol which did not 
bind was not reduced by increasing the column bed column or by 
reducing the amount of cholesterol applied.
The aqueous solution of labelled cholesterol was then incubated 
with BSA (400jJg BSA with 94 pmol [3H]- cholesterol) at 37°C
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Figure 3.2.1.1 Elution profile obtained when 141 pmol [ 3H] -cholesterol was applied 
to a Lipidex 1000 column at 4 °C
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Figure 3.2.1.2 Elution profile obtained when 141pmol [3H] - cholesterol 
was applied to a Lipidex 1000 column at 30 °C.
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for 30 minutes before application to a Lipidex 1000 column 
which was being maintained at either 30°C or 4°C. 
At 4°C only 67% of the labelled cholesterol bound to 
the Lipidex 1000 Column, which was 12% less than that bound in 
the absence of BSA. This portion presumably represented BSA 
bound cholesterol (0.028 pmol/^g BSA). While the amount of 
cholesterol bound by BSA is low., the binding is still easily 
detectable using a Lipidex 1000 column. At 30°C, the 
percentage binding of cholesterol to the column was 82% which 
equals the percentage bound in the absence of protein. This 
suggests that at this temperature all BSA bound cholesterol was 
removed by the column (Figure 3.2.1.3) as already reported for 
protein bound fatty acids (Glatz and Veerkamp, 1983). Thus it 
appeared that a column of Lipidex 1000, at 4°C, was suitable 
for the separation of protein bound and free cholesterol. 
However, prior incubation of purified SCP with the labelled 
cholesterol did not lead to any change in the elution profile 
of the column, when run at 4°C (Figure 3.2.1.4). Therefore, 
the concentration of free label was not affected by the 
presence of SCP, which indicates that SCP did not bind any 
cholesterol during the incubation step.
3.2.1.2 Studies with Activated Charcoal as the Separating
Agent
Charcoal is known to adsorb small hydrophobic molecules in a 
time and temperature dependent manner and is commonly used in 
binding studies to separate bound from free ligand. As a large 
number of different protocols for charcoal have been reported, 
it was first necessary to establish those conditions which 
would be optimum for separation of bound and free cholesterol. 
Various charcoal preparations were examined as shown in Table 
3.2.1.1. The presence of Dextran and/or gelatin was found to 
reduce, substantially, the binding of free label by charcoal 
and hence increase non-specific binding. It was found that 
minimum non-specific binding occurred when a simple suspension 
of 0.7% (w/v) charcoal in PBS (pH 7.4) was used.
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Figure 3.2.1.3 Elution profile obtained when a mixture of 400ug BSA and 94 pmol 
[ 3H] - cholesterol was applied to a lipldex 1000 column at 4°C ( ) 
and 30°C ( ) BSA and labelled cholesterol were incubated at 30 °C 
for 30 minutes before applying to column.
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Figure 3.2.1.4 Elution profile obtained when a mixture of 8.6ug SCP and 47 pmol
[3H] - cholesterol was applied to a Lipidex 1000 column at 4°C. SCP and labelled 
cholesterol were Incubated at 37 °C for 30 minutes before application to the column.
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TABLE 3.2.1.1. Effect of the presence of dextran and gelatin 
on the binding of free [^ H] - cholesterol by 
0.7% (w/v) charcoal suspensions in PBS.
Charcoal Preparation Binding of Label
to Charcoal 
%
Non-Specific 
Binding of Label 
%
0.7% Charcoal 74 26
0.7% Dextran Coated Charcoal 67 33
0.7% Charcoal and 0.1% Gelatin 49 51
0.7% Dextran Coated Charcoal 
and 0.1% Gelatin 39 61
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To further reduce non-specific binding the percentage charcoal 
was then varied from 0.1-1% (w/v). This resulted in a
continued decrease in non-specific binding of label as the 
percentage of charcoal used was increased. (Table 3.2.1.2). 
The results reported represent an average of 10 identical 
experiments. Because of difficulty encountered with pelleting 
of the charcoal when it was used at greater than 0.7% (w/v) the 
less concentrated suspension of charcoal, 0.7% (w/v), was
chosen for subsequent studies.
The cholesterol binding capacity of SCP was then investigated 
by incubation of the label (0.76 pmol [^H]-cholesterol; 32.9 
Ci/mmol) with varying amounts of the protein and subsequent 
separation of the free ligand by charcoal treatment. The 
presence of SCP (0.lpg-lOOpg/assay tube) caused no change in 
the concentration of free cholesterol measured, thus suggesting 
that no binding of cholesterol by SCP had occurred. However, 
BSA at a concentration of 10 pg/assay tube (the concentration 
used by Glatz and Veerkamp (1983) in palmitate binding studies) 
was found to bind 0.06 pmol of [^ H]-cholesterol. This is 
equivalent to 0.006 pmol/pg BSA. The lower degree of binding 
observed using this method was not totally unexpected as Glatz 
and Veerkamp, (1983) reported that separation of protein-bound 
and free fatty acids by charcoal resulted in a lower apparent 
degree of protein-binding than found with Lipidex 1000. This 
arises due to stripping of the protein-bound ligands by 
charcoal. Nevertheless, binding of cholesterol by BSA was 
clearly demonstrated by this method thereby lending support to 
the lack of cholesterol binding activity by SCP, regardless of 
the concentration tested. Prior delipidation of the SCP 
preparation as outlined in Materials and Methods (Section
2 .2 .2 .3) did not affect the results.
3.2.1.3 Use of Gel Filtration in Separation of Bound and
Free Ligand
Ritter and Dempsey (1973) have reported cholesterol binding by 
a partially purified preparation of SCP. They used gel 
filtration to separate SCP bound from free cholesterol and it 
was decided to attempt to repeat this experiment with the SCP
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TABLE 3.2.1.2 Binding of [^H]-cholesterol to charcoal 
present at varying concentrations
Charcoal Concentration Binding of [^ H]- 
Cholesterol to 
Charcoal
Non Specific 
Binding of 
[3H] - 
Cholesterol
% % %
0 .1 0 100
0.3 66 34
0.5 69 31
0.7 74 26
0.8 80 20
0.9 81 19
1 .0 85 15
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Figure 3.2.1.5 Typical elution profile of [3H] - cholesterol following application to 
a Sephadex G-25 gel filtration column.
Void volume of the column was 9.3ml.
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of higher purity prepared during this study. An aqueous 
solution of labelled cholesterol (7.6 pmol/ml) with a specific 
activity of 32.9 Ci/mmol,’ was applied to Sephadex G-10, G-25 
and G-75 gel filtration columns. However, in all cases the 
label was unexpectedly eluted in the void volume (Figure 
3.2.1.5 depicts a typical profile obtained). Because of its 
low molecular weight, it was expected that free cholesterol 
would be retained by these columns. The results obtained 
indicated that the cholesterol molecules had aggregated to form 
a higher molecular weight structure. The critical micellar 
concenration of cholesterol is reported to be 25-40 nM (25-40 
pmol/ml) at 25°C (Haberland and Reynolds, 1973) and to 
decrease with decreasing temperature. It is possible, 
therefore, that at room temperature, 10-12°C, a 7.6 pmol/ml 
solution of cholesterol would exist as micelles, which would 
then appear in the void volume.
Since Ritter and Dempsey (1971) used a propylene glycol 
solution of cholesterol in their studies rather than an aqueous 
solution, a repeat of their experimental procedure was 
attempted. When the [^ H]-cholesterol solution was prepared in 
propylene glycol, as described in Section 2.2.2.1 and applied 
to each of the individual columns the label was again eluted in 
the void volume (Figure 3.2.1.6 depicts a typical profile 
obtained). Therefore, aggregation of' cholesterol must also 
occur in this solvent. In all cases, approximately 95% of the 
label applied to the column was recovered. Therefore, gel
filtration was found to be unsuitable for the separation of 
protein bound and free cholesterol.
3.2.2 Fatty Acid Binding Studies
There is less dispute in the literature over the fatty acid 
binding property of the protein known as SCP. It was decided 
to investigate the fatty acid binding property of the SCP 
prepared in this study. Since charcoal is the most frequently 
used method of separation for protein-bound and free ligands; 
it was chosen for use in the separation of SCP-bound and free 
oleic acid. A similar protocol was followed as was used in the 
cholesterol-binding studies.
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Figure 3.2.1.6 Typical elition profile of [ 3 H] - cholesterol in propylene glycol 
following application to a Sephadex G-25 gel filtration column. 
Void volume of the column was 9.3ml.
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In the absence of protein, 82% of [%]-oleic acid was bound 
by the charcoal suspension (0.7% (w/v) in PBS buffer (pH 7.4). 
This implies 18% non-specific binding of the label under the 
experimental conditions used. The recovery of free fatty acid 
was substantially reduced by prior incubation of the labelled 
fatty acid with both SCP and BSA indicating that both of these 
proteins have fatty acid binding capabilities. lOjjg BSA was 
found to bind 15 pmoles [^H]-oleic acid while lOjjg SCP was 
found to bind 12 pmoles [^H]-oleic acid. This is equivalent 
to 1.5 pmol/jjg BSA and 1.2 pmol/ jjg SCP. It seems, therefore, 
that the protein purified earlier in this study was indeed 
capable of binding fatty acids, but this study has failed to 
show cholesterol-binding activity by this protein.
3.3 Antibodies to SCP
3.3.1 Antibody Titre Determination
Antibodies to both native SCP and to the SCP band cut from the 
SDS polyacrylamide gradient gels were raised in both female 
Balb C mice and New Zealand White rabbits as outlined in 
sections 2.2.3.1 and 2.2.3.2, respectively. With respect to 
the rabbits, bleeds were taken at regular intervals to monitor 
antibody production. The final bleed, taken following 
boosting, was subjected to immunoglobulin enrichment as 
described in section 2.2.3.3. In the case of the mice ascites 
fluid was collected and stored until no more was produced and 
then it, too, was enriched for immunoglobulin.
A sandwich type ELISA was used in titre determination. Wells 
of the microtitre plates were coated with 10 j^ /well SCP 
estimated to be a large excess - washed well and then reacted 
with varying dilutions of the test antisera (section 2.2 .3.4). 
After washing the wells they were reacted with the appropriate 
second antibody conjugated to the enzyme;- horse radish 
peroxidase (HRP) - donkey anti-mouse IgG-HRP and mouse 
anti-rabbit IgG-HRP. The dilution factor recommended by the 
manufacturers for each of these conjugates was found to be too 
high. Thus a suitable working dilution was determined as being 
that which yielded adequate colour development with the test 
antisera. A dilution of 1 in 2000 was found to be suitable for
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the donkey anti-mouse IgG-HRP conjugate. However, problems 
were encountered with the stability of the commercial mouse 
anti-rabbit IgG-HRP conjugate. Initially the enzyme activity 
was found to be unstable and activity was greatly reduced both 
on storage at 4°C and at -20°C. In replacement batches the 
antibody binding activity of the commercial conjugate was found 
to be unstable while the enzyme maintained its activity. An 
alternative conjugate was kindly donated by the Department of 
Biochemistry, University College, Galway, which proved to be 
more stable and a working dilution of 1 in 400 was established 
for this conjugate.
Antibody titres of rabbit bleeds were determined as outlined 
earlier. The titre was taken as being that dilution which gave 
an O.D49Qnm 1-0* The titre was established by plotting the
O.D^gonm against serial dilutions of the respective antisera. 
A typical plot is illustrated in Figure 3.3.1. The antibody 
titres for the remaining living rabbits before and after 
boosting are outlined in Table 3.3.1.
Large bleeds were taken from all rabbits except R28O which 
showed a poor antibody response. The immunoglobulin fraction 
was partially purified from each bleed (section 2.2.3.3) for 
further characterization. Both groups of mice yielded 
sufficient ascites for further characterization - M^qO which 
were immunized with native SCP and M4Q which were immunized 
with polyacrylamide-gel-incorporated SCP. The total ascites 
collected from each group was pooled and also subjected to 
immunoglobulin enrichment before characterization. The 
resulting enriched immunoglobulin fractions were then assayed 
to determine their respective antibody titres. Titres for both 
ascites samples were low 90 and 990 for M42 and M^00’ 
respectively (Table 3.3.2). Since the volume of enriched IgG 
recovered was also low in both these cases, these samples were 
not subjected to any further characterization. Titres for 
rabbits range from 75 for R262 which was immunized with 
PAG-incorporated SCP to 7,800 for R289 which was immunized with 
native SCP (Table 3.3.2).
This study aimed to produce two antisera with high activity 
towards native SCP. These would enable the development of a
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Figure 3.3.1 Antibody titre determination.
Graph depicts a typical profile obtained by plotting the O.D 490nm 
Vs. diluted antisera.
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TABLE 3.3.1 Summary of rabbit anti-SCP Titres pre and post­
boosting
Animal Immunogen
Route of 
Immunization
Maximum
Rabbit
Pre-Boost
(a)
Titres of 
Bleeds
Post-Boost
r262 PAG-incorporated SCP
(b)
I.D. 325 880
r279 II It ti I.D. 460 2,060
r280 i t  i t n I.D. 95 435
r 282 Native SCP
(b)
S.C. 880 2,600
r284 it  it I.D. 1,125 3,000
r289 ii n I.D. 1,530 3,500
(a) Titres are expressed as the reciprocal of the dilution factor 
giving an O.D. 490 of 1.0.
(b) I.D. - Intradermal injection 
S.C. - Subcutanous injection
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TABLE 3.3.2 Anti SCP titres of immunoglublin enriched 
ascites and antisera
ANIMAL IMMUNOGEN ROUTE OF 
IMMUNIZATION
VOLUME OF 
ENRICHED Ig 
(ml)
TITRE
m42 PAG-incorporated 
SCP I.P. * 0.5 90
M100 Native SCP I.P. * 0.5 990
R262 PAG -incorporated SCP I. D. * 2.5 75
r279 PAG-incorporated SCP I.D. * 2.75 200
r282 Native SCP S.C. * 3.0 470
r284 Native SCP I.D. * 4.0 6,600
r28 Native SCP I.D. * , 4.2 7,800
* Route of immunization-
I.P. - intraperitoneal 
X.D. - intradermal 
S.C. - subcutaneous
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sensitive sandwich enzyme immunoassay for SCP in biological 
systems (i.e. native SCP). Thus the antisera from the two
rabbits K-284 an<* ^289 > which were immunized intradermally 
with native SCP, were selected for further characterization.
3.3.2 Antibody Specificity
It was necessary to determine the specificity of antisera R-284 
and K-289- The major expected cross reactants were the 
DEAE-Peak I protein, which co-purified with SCP up to a certain 
stage of the purification procedure, and albumin, which is the 
major extracellular fatty acid binding protein and hence might 
share common antigenic determinants with SCP. Cross reactivity 
towards gelatin was also determined. Wells of a microtitre 
plate were coated with these proteins at two concentrations, 10 
and 100 pg/well and the colour obtained compared with that 
obtained with SCP coated at lOjjg/well. Results indicated that 
neither antisera R284 n o r  R289were active against DEAE-Peak I 
protein or gelatin. In addition the antisera from R284 was not 
found to show any reaction to BSA while R289 showed a slight 
response aga'inst BSA, equivalent to 4.5% cross reaction (Table
3.3.3).
3.3.3 Antibody Sensitivity
For the determination of antibody titres the wells of 
microtitre plates were each coated with lO^g of purified SCP 
(Section 2.2.3.4). In selecting this coating concentration, it 
was assumed that this quantity of SCP was an excess. It was 
necessary, therefore, to determine the sensitivity of the 
antisera R284 an<^- -^289 against SCP. Wells were coated with
SCP concentrations which ranged from 0.1jjg/ml to 10yg/ml (i.e. 
0.02jjg/well to 2^ jg/well) . Both enriched IgG preparations were 
used at 1 in 5000 dilution for these experiments. With both 
antibody preparations, the colour response was found to 
increase as coating concentration increased from 1 to lO^g/ml 
(Figure 3.3.2). The degree of colour obtained with R289 was 
slightly higher than that obtained with R284 (Figure 3.3.2). 
At concentrations below ljjg/ml the colour produced was not 
significantly different from background with either of the IgG
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TABLE 3 . 3 . 3 . Reaction of anti'sera R284 and R289 against 
different proteins
PROTEIN SAMPLE PROTEIN CONCENTRATION O.D.490
( g/well) r284 r289
SCP 10 1.123 1.242
DEAE-Peak I 10 0 0
BSA 10 0 0.145
BSA 100 0 0.056
Gelatin - 10 0 0
Gelatin 100 0 0
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Figure 3.3.2 Detrermlnatlon of the sensitivity of the IgG preparations R ( ) 
and R 289 ( ) toward SCP.
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preparations.
These results indicate that both selected antisera can be used 
to detect 0.2 pg of SCP and upwards when the protein is coated 
directly onto the plate. The coating step Is, however, 
generally accepted to be less than 100% efficient. Therefore, 
in a sandwich assay where all SCP present in the sample would 
be trapped by a solid phase antibody to SCP, the detection 
limit would be expected to be lower than this value.
Thus this study has resulted in the production of two anti-SCP 
antisera which show sufficient specificity in their binding 
towards SCP. They can be used to detect SCP levels at least as 
low as 0.2jjg and their titres are such that they are available 
in adequate quantities for development of a sandwich ELISA for 
SCP.
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DISCUSSION
The object of this project was to purify SCP from rat liver; 
clarify its lipid binding properties and lay the ground work for a 
rapid and sensitive assay for SCP. This study was initiated as a 
result of the observation that SCP is also found in serum where it 
is mainly associated with the lipoprotein fraction (Dempsey et 
al., 1984a). It is, therefore, not solely an intracellular 
protein. It was of interest to investigate the mechanism of 
association between SCP and the various lipoproteins which it was 
thought might involve binding of SCP to cholesterol on the surface 
of the lipoprotein particle. In addition serum SCP levels have 
more recently been found to be elevated in individuals suffering 
from atherosclerosis (unpublished data). A rapid and sensitive 
assay would prove useful in further studies on serum levels of 
SCP. The assay system which has been used to date does not lend 
itself to rapid screening of large numbers of samples. Hence, 
this study also aimed to initiate the development of such an 
assay. For both of these objectives purified SCP was required, 
which was prepared in the first part of this study.
Purification of SCP was performed according to the the method of 
Dempsey £t al., (1981). On all occasions, the protein profile 
obtained following gel filtration was identical to the reported 
observations of Dempsey et al., (1981). 'Many of the protein 
profiles following ion-exchange chromatography were also as 
reported by Dempsey et al., (1981). However, in some instances 
the protein, which bound to the column, formed two distinct peaks 
when eluted with NaCl; the smaller extra peak (DEAE-Peak Ila) was 
* eluted prior to the major second peak (DEAE-Peak II or SCP). 
While no such peak has been reported in the literature pertaining 
directly to SCP, it has been observed that FABP, Z-protein and 
Protein A (Glatz and Veerkamp, 1985; Trulzsch and Arias, 1981; 
Takahashi et al., 1983 and Ketterer £t al., 1976) gave a number of 
peaks following ion-exchange chromatography. These differences 
have been attributed to the presence or absence of specific fatty 
acids bound to the protein when isolated, which would ultimately 
affect the isoelectric point of the protein and thus its elution 
profile when subjected to ion-exchange chromatography. It was 
noted, in this study, that the smaller peak (DEAE-Peak Ila) 
occurred only when older animals were used as the source of the
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protein, i.e. animals greater than 300 g body weight. Dempsey et 
al. , (1981) only reported the use of animals between 200-250 g
body weight. The different profile in older animals may be due to 
different distribution of fatty acids in the SCP of older animals.
Many of the reported functions of SCP, e.g. cholesterol 
synthesis, adrenal steroidogenesis would require an ability to 
bind sterol precursors and cholesterol itself. Ritter and Dempsey 
(1973) reported binding of cholesterol and its esters by a crude 
preparation of SCP. However, Scallen et al., (1985) could not 
attribute any sterol carrier protein activity to FABP (a protein 
believed to be identical to SCP). FABP was not capable of 
releasing cholesterol from adrenal lipid droplets nor did it 
stimulate the utilization of endogenous mitochondrial cholesterol 
for pregnenolone production. These assays were designed to mirror 
the physiological role of a carrier protein. No organic solvents 
were used (Scallen et al., 1985). In this study an attempt was
made to clarify the sterol binding capacity of purified SCP using 
conventional binding assay methodology. No binding of cholesterol 
by SCP was observed during these studies regardless of the method 
used. However, BSA was found to bind cholesterol in aqueous 
solution using two different methods for separation of 
protein-bound and free ligand. The degree of binding was very low 
as expected, since physiologically albumin does not contribute 
significantly to cholesterol transport. The discrepancy in the 
results obtained by the two methods (0.028 pmoles cholesterol/ g 
BSA using Lipidex 1000 and 0.006 pmoles/ g BSA using charcoal) was 
not unexpected as Glatz and Veerkamp (1983) reported that Lipidex 
1000 was much more effective in the separation of bound and 
unbound fatty acid than charcoal.
In 1973, when Ritter and Dempsey reported cholesterol binding by a 
crude preparation of SCP, they used gel filtration to separate 
unbound from protein-bound ligand. During this study, an attempt 
was made to repeat these results using purified SCP. However, 
initially the cholesterol was prepared in aqueous solution rather 
than propylene glycol to avoid introduction of an organic solvent 
which was considered to be non-physiological. It was found that 
regardless of the exclusion limit of the gel used (Sephadex G-75 
3,000-70,000 Daltons; Sephadex G-25 100-5,000 Daltons and Sephadex 
G-10 0-700 Daltons) free cholesterol was eluted repeatedly in the
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void volume. Such a finding was unexpected as cholesterol, having 
a molecular weight of 387 Daltons, should have been retained by 
each of the gels used. It has been reported that cholesterol
undergoes thermodynamically reversible self-association in aqueous
solution with a critical micelle concentration of 25-40 nM at 
25°C (Haberland and Reynolds, 1973).
This concentration is' higher than that used in the experiments 
reported here (cholesterol at a concentration of 7.6 pmol/ml was 
used). However, the different temperatures at which experiments 
were performed may result in a different critical micellar 
concentration. This reversible self association of cholesterol is 
believed to yield a rod shaped micelle with a molecular weight of 
approximately 200,000 Daltons. This would readily explain the 
elution of the cholesterol in the void volume.
When the experiments were repeated using propylene glycol as the 
solvent for the cholesterol as reported by Ritter and Dempsey 
(1973), the cholesterol was still found to be eluted in the void
volume regardless of the gel used. This suggests that some
aggregation of cholesterol also occurred in this solvent. In 
their report Ritter and Dempsey (1973) do not show the results 
obtained from a blank run, i.e. when the cholesterol alone was 
applied to the column, so one must presume that they did observe 
retention of the free cholesterol. It is therefore difficult to 
explain the different results observed. The presence of 
phospholipid has been reported to be necessary for the binding of 
cholesterol by high density lipoprotein (Sodhi and Gould, 1967). 
It is possible that the presence of phospholipid in the impure SCP 
preparation of Ritter and Dempsey (1973) may have influenced the 
results obtained. The results presented in this thesis, however, 
strongly support those of Scallen et al., (1985) who failed to 
show any involvement of FABP (i.e. SCP) in physiological reactions 
involving cholesterol transfer. They attribute cholesterol 
binding activity to another low molecular weight protein, SCP2, 
which differs significantly from SCP in amino acid composition. 
They claim that the protein referred to in this thesis as SCP 
functions in fatty acid binding and/or transport. This study has 
confirmed the fatty acid binding of SCP; 1.2 pmoles oleic acid was 
bound per g SCP as it was isolated, i.e. without delipidation.
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Maximum binding of dealbuminised rat liver cytosol was reported as 
being 4.39 pmol/^ jg protein by Glatz and Veerkamp (1983). This 
value is considerably higher than the values presented in this 
thesis for fatty acid binding by pure SCP. However, it should be
noted that the fatty acid binding observed was reported to be
dependent on the concentration of fatty acid used and that at low 
fatty acid concentrations, as were used in this study, prior
delipidation of the test protein resulted in a significant 
increase in fatty acid binding. In the studies reported in this 
thesis SCP was not delipidated prior to faty acid binding studies. 
Finally, the effect of using cytosolic proteins, some of which 
may have fatty acid binding activity in addition to that exhibited 
by SCP, cannot be ruled out. The presence of such proteins could 
artifically elevate the apparent fatty acid binding activity of a 
single protein, in this case SCP.
This study was initiated following a report by Dempsey (1984a)
that SCP was found in serum where it was primarily associated with 
the high density lipoprotein fraction. Jhe mechanism of 
association of SCP with HDL was thought to be related to the 
cholesterol binding properties of SCP as was reported by Ritter 
and Dempsey (1971, 1973). However, in this study we were unable 
to demonstrate cholesterol binding by SCP which thus leaves the 
question of the mechanism of the reported association of SCP with 
HDL unanswered. However, it is possible that SCP may bind to the 
HDL particles via phospholipid mediated cholesterol binding. 
Therefore, further work incorporating phospholipid into the 
binding studies mentioned is required before an ability to bind 
cholesterol by SCP can be ruled out.
The third aim of this project was to carry out the initial stages 
in the development of a sensitive assay system for measurement of 
SCP levels in serum. It was believed that a sandwich enzyme 
linked immunosorbent assay would ultimately yield a suitable 
system. As mentioned earlier, such an assay would require two 
different antibody preparations with high specificity for SCP.
One antibody preparation, the solid phase antibody, would capture 
the antigen molecules from the sample. They would then be 
available for reaction with the second antibody preparation which 
would be enzyme-conjugated to permit detection. The two
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antibodies need to be directed against different antigenic sites 
on the antigen in a sandwich assay unless the antigen is known to 
have some kind of symmetry and hence replicating antigenic 
determinants.
SCP is a relatively small protein (approximately 14,000 Daltons 
(by amino acid analysis, Dempsey, 1985)) and therefore some 
difficulty was expected in generating an immune response to this 
protein. Therefore, antibody production was approached from a 
number of different angles. Earlier studies indicated that 
SDS-PAG-incorporated SCP generated an immune response in rabbits 
(McGuire et al., 1984). Thus this was one of the selected methods 
for this study. This method has the advantage that the purity of 
the immunogen is ensured, being a single band from a previously 
run SDS-polyacrylamide gel. However, since SDS was required for 
better resolution of SCP from any possible contaminating proteins, 
the immunogen, SCP was not in its native state. Therefore, 
undenatured SCP was also used as immunogen in a second set of 
animals. There are various reports on the efficiency of various 
routes of immunization in rabbits. Hence both intradermal and 
subcutaneous sites were used with each immunogen. Following a
report by Tung (1983), production of antibodies to both 
PAG-incorporated and native SCP in mice by intraperitoneal 
injection was also attempted.
During the course of this study only two antisera were produced 
with sufficiently high titre and exhibiting a high degree of 
selectivity and sensitivity. Both were produced following 
intradermal injection of native SCP into rabbits. Both were found 
to be able to detect SCP at leyels of 0.2pg/well when SCP was 
coated directly onto the well and using a commercial second 
antibody-enzyme conjugate. The concentration of SCP in human
serum has been reported to be in the range of 13.7 - 17.9 mg/dl
(Cunningham, 1985). The average sample volume used in ELISA
systems is 50 pi. This volume of serum would contain 
approximately 8 yg of SCP based on the above data. Thus, both 
antisera generated during this study are sufficiently sensitive 
for use in an assay of SCP in serum.
The specificities of both IgG preparations were found to be 
different. P-284 on -^y reacted with SCP while K-289 reacted with
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both SCP and BSA. The reaction with BSA was low but was, however, 
detectable under experimental conditions used. Cross-reaction of 
the antibody with BSA was not unexpected as both proteins have 
fatty acid binding properties and therefore, possibly have 
antigenic sites in common. The observed difference in specificity 
suggests that the two sets of antisera are directed against 
different antigenic determinants and therefore suitable for use in 
a sandwich assay for the reasons outlined earlier.
The assay system used in this study, involving direct binding of 
SCP to microtitre plate wells followed by reaction with one of the 
anti-SCP antibody preparations and use of a second antibody-enzyme 
conjugate for detection, is only suitable for measurement of
purified SCP. The long-term aim of this work was to provide an 
alternative assay system for SCP in serum or serum fractions which 
would be simpler and less time-consuming than the 
immuno-precipitation assay used to date (Conneely et al., 1984).
It was not feasible during the present study to complete the 
development of the sandwich ELISA for SCP which is needed to 
measure SCP levels in complex mixtures such as serum. To achieve 
this goal an enzyme-anti-SCP conjugate would have to be prepared.
A number of different methods are available for enzyme-antibody
conjugate preparation. Much difficulty was encountered during 
this study with the stability of commercial second 
antibody-enzyme preparations. Both enzyme and immunological 
activities showed instability at various times. Details of
methods of preparation were not available and so possible reasons 
for these problems were not clear. The HRP-anti rabbit 
IgG-conjugate finally used in this study, which was provided as a 
gift, was produced by Maleimide conjugation of the F ab portion of 
the antibody to HRP by the method of Ishikawa et al., (1983). 
This enzyme antibody conjugate preparation was found to be very 
stable when stored at 4°C. It is recommended that the 
anti-SCP-enzyme conjugate be prepared, initially, by a similar 
method and that due attention be given to checking stability of 
the product under different conditions of storage.
In conclusion, therefore, in this study SCP was isolated and 
purified from rat liver. The purified protein was used in 
conventional lipid binding studies which indicated that SCP is a 
fatty acid binding protein without the ability to bind cholesterol
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under the experimental conditions examined. This work lends 
support to similar recent conclusions made about this protein 
based on experiments which investigated its physiological 
function. Two antisera of high specificity and sensitivity have 
been prepared and are available in sufficient quantities to be 
used in- the further development of a sensitive and quantitative 
sandwich ELISA for SCP.
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APPENDIX
1
ABBREVIATIONS USED
SCP Sterol Carrier Protein
SCPi Sterol Carrier Protein^
SCP2 Sterol Carrier Protei^
SPF Supernatant protein Factor
ns L-TP Non-Specific Lipid-Transfer Protein
CRBP Cellular Retinol Binding Protein
CRABP Cellular Retinoic Acid Binding Protein
FABP Fatty Acid Binding Protein
CSCC Cholesterol Side Chain Cleavage
SDS Sodium Dodecyl Sulphate
PAG Polyacrylamide Gel
RIA Radioimmuno Assays
EIA Enzyme Immuno Assays
ELISA Enzyme Linked Immuno Sorbent Assay
HRP Horse Radish Peroxidase
Fab F Antibody
HDL High Density Lipoproteins
LDL Low Density Lipoproteins
VLDL Very Low Density Lipoproteins
(i)
